problem solving intervention to address comorbid diagnoses

To read this content please select one of the options below:

Please note you do not have access to teaching notes, adapting the incredible years child dinosaur social, emotional, and problem-solving intervention to address comorbid diagnoses.

Journal of Children's Services

ISSN : 1746-6660

Article publication date: 4 May 2008

Young children who are referred to mental health agencies because of oppositional defiant disorder (ODD) and conduct problems (CP) frequently have comorbid diagnoses or symptoms such as attention deficit disorder (ADD) with or without hyperactivity (ADHD), language/learning and developmental, or autism spectrum disorders. Research has shown that the Incredible Years Child Dinosaur programme offered to children with comorbid issues is successful at reducing behaviour problems and increasing social and emotional competence. This article examines ways in which this small group therapy programme is tailored to address the individual goals of each child so that the intervention is developmentally and therapeutically appropriate. It discusses group composition, as well as the importance of specific content and teaching methods for children with ADHD, academic and language delays and mild autism.

Corrigendum:

It has been brought to Emerald’s attention that the article “Adapting the Incredible Years child dinosaur social, emotional, and problem-solving intervention to address comorbid diagnoses” by Webster-Stratton, Carolyn and Reid, M. Jamila published in the Journal of Children’s Services, Vol. 3 No. 3, 2008, failed to disclose conflict of interests prior to publication. Author Carolyn Webster-Stratton disseminates the Incredible Years treatment and stands to gain from favourable reports. Because of this, she has voluntarily agreed to distance herself from certain critical research activities, including recruitment, consenting, primary data handling and data analyses. The authors apologise for not disclosing the information prior to publication. The University of Washington has approved these arrangements.

Incredible Years group therapy programme
Programme adaptation
Comorbid problems

Webster-Stratton, C. and Reid, M. (2008), "Adapting the Incredible Years child dinosaur social, emotional, and problem-solving intervention to address comorbid diagnoses", Journal of Children's Services , Vol. 3 No. 3, pp. 17-30. https://doi.org/10.1108/17466660200800016

Emerald Group Publishing Limited

All feedback is valuable.

Please share your general feedback

Report an issue or find answers to frequently asked questions

Contact Customer Support

Incredible Years Blog

Check out our blog for social-emotional learning articles, news, and more!

Child Training
Agencies and Administrators
Research Library
Implementation and Dissemination
Therapists and Group Leaders

Adapting the Incredible Years Child Dinosaur Social, Emotional, and Problem-Solving Intervention to Address Co-Morbid Diagnoses

Read the article (PDF)

Webster-Stratton, C., & Reid, M. J. (2008). Adapting the Incredible Years Child Dinosaur Social, Emotional and Problem-Solving intervention to address co-morbid diagnoses. Journal of Children's Services , 3(3), 17-30.

5 Social Emotional Learning (SEL) Classroom Management Techniques

Healthy Parent-Teacher Relationships: Key Tips for Success

How IY Autism Parenting Programs Can Support Families

New Zealand is Truly Incredible

Group-Based Parenting Programs: Strengthening Parental Engagement

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Publications
Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

Advanced Search
Journal List
Popul Health Manag

Care Management of Comorbid Medical and Psychiatric Illness: A Conceptual Framework for Improving Equity of Care

Lisa c. rosenfeld.

1 Department of Psychiatry, Cambridge Health Alliance, Cambridge, Massachusetts, USA.

2 Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.

Philip Wang

Jackie holland.

3 Humana, Inc., Louisville, Kentucky, USA.

Matthew Ruble

Taft parsons, iii, hsiang huang.

Psychiatric and medical comorbidities are common among adults in the United States. Due to the complex interplay between medical and psychiatric illness, comorbidities result in substantial disparities in morbidity, mortality, and health care costs. There is, thus, both an ethical and fiscal imperative to develop care management programs to address the needs of individuals with comorbid conditions. Although there is substantial evidence supporting the use of care management for improving health outcomes for patients with chronic diseases, the majority of interventions described in the literature are condition-specific. Given the prevalence of comorbidities, the authors of this article reviewed the literature and drew on their clinical expertise to guide the development of future multimorbidity care management programs. Their review yielded one study of multimorbidity care management and two studies of multimorbidity collaborative care. The authors supplemented their findings by describing three key pillars of effective care management, as well as specific interventions to offer patients based on their psychiatric diagnoses and illness severity. The authors proposed short-, medium-, and long-term indicators to measure and track the impact of care management programs on disparities in care. Future studies are needed to identify which elements of existing multimorbidity collaborative care models are active ingredients, as well as which of the suggested supplemental interventions offer the greatest value.

Psychiatric and medical comorbidities are extremely common among adults in the United States, with 68% of those with mental disorders also having medical conditions and 29% of those with medical conditions also having mental disorders. 1 Due to the complex interplay between medical and psychiatric illness, comorbidities result in substantial health disparities.

People with comorbid conditions tend to have more severe symptoms and greater functional impairment than the general population. 1 Further, these patients have a 2- to 4-fold elevated risk of premature mortality, typically due to cardiovascular disease, and greater health care costs. 2–4 Bearing these facts in mind, there is an ethical and fiscal imperative to develop interventions that address the needs of individuals with comorbid medical and psychiatric conditions (hereafter referred to as “comorbidities”), to reduce both health disparities and care costs.

One evidence-based approach to improving the quality of care and health outcomes for people with chronic diseases is care management. Care managers support patients through assessment, care planning, and care coordination. 5 One specific model of care that uses care managers and has shown promise in addressing the needs of patients with psychiatric illness is collaborative care. This model is a team-based approach that emphasizes using care managers to empower patients to manage their own illnesses; provide decision support tools to ensure measurement-guided, evidence-based care; coordinate the flow of information between various members of a patient's care team; and employ population health strategies, such as patient registries, to track outcomes over time. 6 These interventions are guided by case reviews between the care manager and a consulting mental health specialist (typically a psychiatrist).

Although there is substantial evidence supporting the effectiveness of models of care that utilize care managers, including for reducing disparities among racial and ethnic minorities, 7 the majority of interventions described in the literature are disease-specific. Given the prevalence of comorbidities in the general population, single-disease care management programs may be less practical to implement and less efficient for improving outcomes than programs that target multiple conditions at once.

For this reason, the authors of this article reviewed the literature on care management models that target both medical and psychiatric outcomes with the goal of enhancing an existing insurance-based care management program for people with comorbidities. The findings of this review are summarized in the next section. Given the relative paucity of literature on interventions that measure both medical and psychiatric outcomes, the authors supplemented their review by outlining a conceptual framework for the development of care management programs serving individuals with mental and physical comorbidities.

Although the framework described below was initially created to serve the needs of Medicare-eligible beneficiaries, the authors believe these recommendations are broadly applicable and important considerations when developing any care management program that aims at improving health equity for individuals with medical and psychiatric comorbidities.

Evidence-Based Models

The authors reviewed the literature to identify studies of care management programs that aimed at improving medical and psychiatric outcomes for patients with comorbidities. Although there were numerous studies examining the impact of such programs on mental health outcomes 6 or non-specific scores of physical well-being or functional status, 8 , 9 there were relatively few that measured outcomes for both medical and psychiatric conditions.

Of the studies that did measure both sets of outcomes, the interventions fell predominantly into one of two categories: traditional care management programs and collaborative care interventions.

With regard to traditional care management, the authors identified one randomized controlled trial 10 that followed two pilot studies, 11 , 12 all of which were rated as “fair” in quality in a systematic review of care management interventions targeting multimorbidity. 13 This randomized controlled trial examined whether integrating depression and diabetes care management improved adherence to medication regimens, as well as outcomes for both depression and diabetes.

The trial included 180 participants who were treated at a single community-based primary care practice in West Philadelphia. The intervention utilized two research coordinators (one bachelors- and one masters-level) as care managers. The care managers received training on pharmacotherapy for depression and diabetes, as well as on culturally competent evidence-based strategies for quickly building rapport.

The role of the care managers was to help patients recognize depression in the context of their medical illness, explain the rationale for treatment with medications, monitor medication adherence, and help address medication side effects. In addition, medication adherence was tracked by using electronic devices that registered when pill bottles were opened. Over the 3-month study period, the care managers met with study participants three times in-person for 30 minutes, and two times by phone for 15 minutes. Baseline demographic and clinical features did not differ between the two study arms.

At the 3-month follow-up, the trial found statistically significant improvements in medication adherence, depression scores, and diabetes outcomes for participants in the intervention group as compared with the usual care group. Although the limitations of this study include questions about generalizability, restriction to patients with comorbid depression and diabetes, and a short follow-up window, strengths include its low level of resource intensiveness (given no involvement from a mental health specialist) and its inclusion of majority African American study participants, who have long suffered from health disparities. 14

With regard to the collaborative care model, the first of two studies was TEAMcare, 15 which was rated as “good” quality in the aforementioned systematic review of multimorbidity care management programs. The TEAMcare study was an offshoot of the Pathways study (a program aimed at improving depression and diabetes outcomes through enhanced depression care 16 ). The creators of Pathways hypothesized that un- or under-treated depression interfered with self-care behaviors, and that reductions in depressive symptoms would lead to improvements in diet, exercise, and medication adherence, which, in turn, would result in improvements in diabetes outcomes.

However, the Pathways study ultimately found that depression care management alone did not result in improved diabetes outcomes. As a result, TEAMcare was developed to test whether a primary-care based care management program that simultaneously targeted depression and common comorbidities—specifically, diabetes, hypertension, and hyperlipidemia—could improve outcomes across these diagnoses.

TEAMcare enrolled 214 patients (mean age 57) from 14 primary care clinics in Western Washington. The intervention used nurse care managers who received a 2-day course in depression care, with emphasis on diagnosis, treatment, and specific therapeutic interventions, including motivational interviewing and behavioral activation. They also received a refresher course in active management of the three medical conditions listed earlier.

The nurse care managers led structured visits with patients every 2 to 4 weeks, focusing on disease self-management, development of individualized care plans, careful monitoring of outcome measures (such as hemoglobin A1c for diabetes), and relentless adjustment of interventions to achieve the desired health outcomes, also known as “treat-to-target.” The care managers also maintained a patient registry that was reviewed in weekly supervision with a psychiatrist, primary care physician, and psychologist, all with an eye to patients who were new or not responding to treatment as expected.

Over the course of the 12-month study, intervention group participants experienced greater improvements in the composite primary outcome measure—which included SCL-20, hemoglobin A1c, low-density lipoprotein, and systolic blood pressure—than control group participants. 15 Intervention group participants also experienced greater improvements in secondary measures, such as quality of life and satisfaction with care. Further, in a 2-year follow-up study assessing cost-effectiveness, the intervention group had a nearly $600 reduction in outpatient costs, even after accounting for the costs of the intervention. 17

Thus, TEAMcare demonstrated the cost-effectiveness of a primary care-based program in which one medically trained nurse care manager had regular access to a consulting mental health specialist and simultaneously addressed patients' psychiatric and medical gaps in care.

The second collaborative care study, COMPASS, was a dissemination project that included a much larger sample size ( n = 3609) across a broader range of settings. 18 , 19 COMPASS included 18 medical groups spanning 172 primary care and multi-specialty clinics, with between 51 and 684 participants each, across 8 states (in a mix of rural, suburban, and urban settings).

Although the intervention offered in COMPASS was modeled directly after TEAMcare, it did allow for some customization to suit local needs and constraints. For instance, treat-to-target protocols were adapted to regional prescribing practices and care managers were recruited from a variety of backgrounds and specialties. Some offered blended in-person and phone-based care management, whereas others were exclusively phone-based.

Finally, some opted to add members to their systematic case review teams, such as pharmacists, social workers, and diabetes educators. As with TEAMcare, COMPASS was associated with clinically and statistically significant improvements in both psychiatric and medical outcomes. Outcomes did not vary based on the training or background of the care managers.

Given the relative paucity of data, combined with the great need to serve patients with comorbid medical and psychiatric conditions, the authors of this article supplemented the earlier cited review with a conceptual framework that includes “General considerations” and “Specific interventions” to keep in mind when developing care management programs for this patient population.

General Considerations

The considerations that follow are informed by the current literature review and by clinical expertise among the authors. The first consideration is whether to match patients with one or two care managers to address their medical and psychiatric disorders. The authors strongly recommend pairing each patient with a single care manager. Doing so will reduce the risk of miscommunication and duplication of services, thereby leading to more efficient care.

It will also foster a sense among patients that their assigned care manager is their “go-to” person, which will likely breed trust and cut down on confusion. Finally, and perhaps most importantly, assigning a single care manager will allow programs to be nimble enough to address patients' care gaps in the order that is most important to them, which is pivotal to upholding the principle of patient autonomy.

The second consideration is what qualifications a care manager must have to serve in this role ( Fig. 1 ). All else being equal, this should be determined by a patient's primary psychiatric diagnosis. For individuals with mild to moderate anxiety, depression, and substance use disorders (SUDs), registered nurses with competence in assessing clinical status and medication adherence and tolerability would ideally serve in the role of care manager.

An external file that holds a picture, illustration, etc.
Object name is pop.2021.0366_figure1.jpg

Recommended qualifications for care manager, stratified by patient's primary psychiatric disorder.

Alternatively, for patients with serious and persistent mental illness (such as bipolar or schizophrenia) or severe mood, anxiety, or SUDs, care managers with behavioral health expertise (such as a social worker or licensed mental health counselor) would be better suited for the role. 6 Even more important than the specialization of care managers, 20 however, is ensuring (1) access to adequate training and continuing education, (2) an even distribution of complex cases across care managers to reduce burnout and foster a sense of efficacy, and (3) consistent supervision that includes case reviews with a mental health specialist, 21 primary care provider, and clinical pharmacist. 22 , 23

Of note, the provision of regular supervision with specialists has previously been identified as an active ingredient in the collaborative care model. 24 , 25 Ideally, this supervision should focus on planning interventions for new patients, problem solving for patients not responding to interventions as expected, gathering input on medication adjustments and management of side effects, and getting guidance on how to approach challenging patient encounters.

If possible, programs should also offer as-needed supervision of care managers with medical specialists to consult on patients with rare or complex conditions. This additional supervision could be conducted in groups to facilitate ongoing education, mutual support, and efficient use of specialist time.

The third consideration in the design of a care management program is how to prioritize among gaps in care for individuals with disparities across multiple health conditions. In general, the authors recommend following a patient's lead, as doing so will enhance buy-in to a process that will likely require behavior change and may even lead to a virtuous cycle in which making progress on one goal leads to increased confidence in one's ability to make progress on another.

Further, honoring individual preferences about which gaps to tackle first will allow care managers to focus on behavioral medicine principles that cut across diseases, such as disease self-monitoring, 26 medication adherence, 10 , 27 healthy diet, 28 and increased physical activity, 27 , 28 rather than on the specifics of any one condition. In rare cases where members do not have a preference or are unable to communicate a clear preference, behavioral health needs should be addressed before physical needs in patients with severe pathology, such as bipolar affective disorder and schizophrenia.

For all other patients, the authors agree with the approach taken in the studies identified in the literature review, which was to simultaneously address patients' behavioral health needs and common medical risk factors for downstream events, namely hypertension, hyperlipidemia, diabetes, and tobacco use.

The final consideration is what to include in the training of care managers. The authors argue that training is critical and should focus on three key pillars of effective care management ( Fig. 2 ), which are discussed next in detail:

An external file that holds a picture, illustration, etc.
Object name is pop.2021.0366_figure2.jpg

Three key pillars of effective care management.

1. Measurement-based care
2. Motivational interviewing
3. Care coordination

Measurement-based care (MBC) is “the systematic administration of symptom rating scales and use of the results to drive clinical decision making.” Although MBC has been more widely adopted in medical than psychiatric models of care, there is good evidence to support its use in mental health care. A systematic review of 51 studies provided ample evidence that MBC, when conducted frequently and synced with care, led to improved mental health outcomes as compared with usual care. 29

The MBC can be used to systematically identify patients for interventions, which has been identified as an active ingredient of collaborative care models in multiple studies. 20 , 25 Further, MBC can guide conversations (1) with patients about how treatment is progressing and to motivate change, (2) when reviewing caseloads with the entire care management team, especially to help in identifying people not responding to treatment as expected, and (3) to frame treatment recommendations that care managers make to patients' individual physicians and other care providers.

Finally, although the purpose of MBC is to guide the treatment of individual patients, an added benefit is that the data collected can also be used to assess the impact of care management programs more broadly, which is discussed in more detail under the Measuring Impact section.

Motivational interviewing (MI) is a therapeutic technique that aims at resolving ambivalence by tapping into a person's individual reasons for behavior change. 30 Although MI was originally developed for the treatment of SUDs, there is now robust literature supporting its use in a range of applications, such as weight loss, blood pressure control, cholesterol control, and treatment adherence. A meta-analysis of MI revealed that encounters as brief as 15 minutes can lead to significant outcomes, and that more encounters are associated with a greater impact. 30 This same analysis revealed that outcomes did not depend on the level of training of the person performing MI. By implementing MI, care managers can help patients identify personalized treatment goals, improve treatment engagement, and make healthy lifestyle choices.

Finally, poor communication between medical and mental health care systems results in health disparities for individuals with comorbid conditions. 31 Thus, coordinating care by ensuring the timely flow of information between medical and mental health providers regarding upcoming appointment times, recent visits, and medication changes is highly valuable. To bring care coordination to the next level, care managers should focus on prevention.

At its most basic, this means ensuring access to preventive services such as immunizations and cancer screenings, which people with comorbidities have historically received at lower rates than the general population. 32 , 33 Further, this involves monitoring for downstream complications of psychiatric medications, such as metabolic syndrome, which result in morbidity, mortality, and high cost care. 34 Finally, care teams should work to prevent polypharmacy, which results in not only decreased medication adherence but also drug–drug interactions that lead to medication toxicity, delirium, falls, urinary incontinence, and avoidable admissions. 35

Specific Interventions

In this section, the authors recommend specific interventions that have the potential to improve outcomes and reduce disparities if incorporated into care management programs for people with medical and psychiatric comorbidities. Some of these interventions have universal applicability, whereas others should be tailored to an individual's psychiatric diagnosis and illness severity ( Fig. 3 ). The list given next, which includes evidence-based, high value interventions, is not exhaustive. Further, the boundaries delineated between the sub-populations of patients listed are not rigid.

An external file that holds a picture, illustration, etc.
Object name is pop.2021.0366_figure3.jpg

Recommended evidence-based interventions, stratified by psychiatric diagnosis and illness severity.

Universal interventions

The authors strongly recommend that any care management program serving individuals with comorbidities include an evidence-based cigarette smoking cessation intervention. Tobacco use is the leading preventable cause of death and a risk factor for some of the most common conditions among individuals with medical and psychiatric comorbidities. 36 Smoking is more prevalent among people with psychiatric disorders than for people in the general population, thereby contributing to health disparities. 37 The majority of cigarette smokers want to quit, but they need support to do so. 38

Effective smoking cessation treatments exist, and people who succeed in quitting experience improvements in their mood and anxiety, regardless of whether they have an underlying psychiatric illness. 39 , 40 Finally, smoking cessation programs are an excellent return on investment. Studies estimate that they cost just $0.50 per person-month to operate, 41 result in $9800 lifetime savings, 42 and can pay for themselves in as little as 3 years. 43

All eligible patients should also be offered a curated list of health apps. Two systematic reviews of health apps for anxiety and depression, respectively, show early evidence of efficacy in alleviating symptoms. 44 , 45 Although the available data are less compelling for apps to help with weight management and substance use, the authors of this article have worked with patients who have responded to these sorts of apps. Given the low-cost, if not free, nature of health apps, there is potential benefit and little risk in making a variety of health apps broadly available.

Interventions for mild anxiety and depression

Many cases of mild anxiety and depression are the product of social isolation, 46 a problem that has become increasingly prevalent in the context of the COVID-19 pandemic. 47 Certain groups—such as immigrants, elderly individuals, and victims of abuse—are at a particularly high risk of loneliness, resulting in mood and anxiety problems. 46 Prior studies have observed that social deprivation can pose as great a threat to both mental and physical health as obesity and smoking. 48

For this reason, the authors believe that offering interventions that increase social connectedness to patients whose primary behavioral health need is mild anxiety or depression is a worthwhile investment. One such intervention is group therapy, which is cost-effective, has evidence across a range of psychiatric disorders, and may offer particular benefit for patients who are homebound, such as elderly individuals with physical disabilities. 49

Another possible intervention is interactive voice response (IVR) technology, a robocaller that can adapt its messages based on patient feedback and can offer supportive messages, track and encourage adherence to treatment, and triage to human support if needed or requested. 50 Despite being minimally resource intensive, IVR technology is sufficiently lifelike that patients report feeling cared for and cheered up by IVR calls, with corresponding improvements in depression measures. 51

Interventions for moderate anxiety and depression

For patients with moderate anxiety and depression, a combination of brief therapeutic interventions carried out by the care manager, referral to structured psychotherapy with a specialist, and medication management should be offered based on patient preference.

Regarding therapeutic modalities, care managers could offer behavioral activation, an evidence-based intervention that discourages avoidance behaviors and encourages engagement in pleasurable activities. Studies of behavioral activation reveal evidence of equal efficacy when compared with cognitive behavioral therapy (CBT), typically considered the gold standard therapeutic intervention for anxiety and depression, even when administered by junior mental health workers. 52

Alternatively, if organizations are unable to train care managers in behavioral activation, care managers could instead assist with referrals to structured psychotherapies, which have been identified as an active ingredient in the collaborative care model. 20 Evidence-based therapies include cognitive interventions (such as CBT or mindfulness-based stress reduction), skills-based interventions (such as problem-solving therapy or pain management), and exposure therapy. 53 , 54

Regarding medications for anxiety or depression, care management programs could either use an existing algorithm—such as the one in TEAMcare, Harvard South Shore's Psychopharmacology Algorithm Project, 55 or the Texas Medication Algorithm Project 56 —or develop treatment protocols that reflect local prescribing practices. Regardless of the medications selected, the algorithms should utilize the treat-to-target approach previously described, with the goal of finding the lowest effective dose to achieve symptom remission.

Interventions for mild SUDs

For patients with mild SUDs, care managers can provide education about recovery-oriented mutual self-help groups, such as Alcoholics Anonymous (AA), Narcotics Anonymous (NA), and Self-Management and Recovery Training (SMART) Recovery. A Cochrane Review of 27 studies with more than 10,000 participants concluded that AA and other similar programs were at least as effective, if not more effective, than other established treatments for SUDs, such as CBT. 57 This review further concluded that these programs produced substantial health care cost savings among people with alcohol use disorder. With more than 60,000 meetings of varying shapes and sizes in the United States, care managers should focus on helping patients identify meetings that are a good fit and problem-solving barriers to attendance.

Interventions for moderate SUDs

Patients with moderate SUDs should be offered the same education about mutual self-help groups as described earlier and should also be offered referral to medication-assisted treatment (MAT). MAT is typically available through specialty addiction or pain clinics, or through primary care offices with specially licensed providers (sometimes referred to as office-based addiction treatment, or OBAT). MAT should be offered to this group not only because there is clear evidence that it saves lives, but also because MAT has been shown to decrease the need for detoxes and treatment of medical sequelae of SUDs, such as HIV or hepatitis, all of which add to rising health care costs. 58 , 59

Interventions for severe psychiatric conditions

For patients with severe pathology—including bipolar disorder, psychosis, and severe depression, anxiety, or SUDs—care managers should prioritize referral to specialty care in psychiatry and then focus their attention on engagement in care, medication adherence, and careful monitoring for medication-related toxicity.

Measuring Impact

To determine whether the aforementioned interventions are having the desired effect on gaps in care for individuals with medical and psychiatric comorbidities, the authors recommend tracking the following short-, medium-, and long-term indicators ( Fig. 4 ).

An external file that holds a picture, illustration, etc.
Object name is pop.2021.0366_figure4.jpg

Indicators to measure the impact of care management programs.

On the order of weeks, one might observe changes in no-shows, prescription fill rates, medication adherence, and other health behaviors such as diet and exercise (“short-term indicators”). These changes could be measured by using a combination of data from billing, pharmacies, self-report, and laboratories. Insurers or health systems might also consider covering the cost of electronic pill boxes and wearables such as pedometers, which—with patient consent—may be able to transmit data directly to care providers or medical records.

On the order of months, one might observe changes in psychiatric symptoms, vital signs, and biomarkers of medical illness (“medium-term indicators”). 15 These changes could be tracked through a combination of patient-reported outcome measures, vital sign measurement, and laboratory data. Insurers or health systems might consider covering the cost of durable medical equipment, such as glucose and blood pressure monitors, which can aid patients in disease self-management and may also be able to transmit data to care providers or systems.

Some of the most important outcomes—such as reductions in medical events, care needs, and health care spending—could take one or more years to observe a difference (“long-term indicators”). For instance, the TEAMcare model demonstrated reductions in outpatient care utilization and spending over the course of two years. 17 Similarly, a study of collaborative care for bipolar disorder revealed reductions in care utilization after two years and reductions in medical spending emerged over the course of three . 60

Finally, one study comparing usual care with a team-based care model in which care managers assisted with patient outreach and care coordination found reduced rates of primary care visits, ambulatory care sensitive visits, emergency department visits, and hospital admissions among patients in the intervention arm over the 3-year study period. 61

Although health care systems with limited resources at their disposal might be reluctant to invest in comprehensive care management programs that could take years to demonstrate impact and cost savings, it is worth noting that medium-term indicators such as those listed earlier can provide insight into whether downstream impact is likely to occur.

For instance, in a UK study of a 1-year diabetes intervention with more than 4000 participants, post-trial monitoring revealed sustained risk reductions in diabetes-related end point, microvascular disease, myocardial infarction, and all-cause mortality 10 years after the study ended, even though between-group differences in hemoglobin A1c were lost after the first year. 62

With this finding in mind, it stands to reason that if care management interventions can lead to improvements in vital signs, biomarkers, treatment engagement, and health behaviors that persist for more than a year, the resulting health improvements and reductions in care costs would be even greater.

Moving Forward

In conclusion, many adults in the United States have comorbid medical and psychiatric conditions, and these individuals suffer from disparities in morbidity, mortality, and social and occupational functioning. Care management programs have the potential to address gaps in care and improve outcomes for individuals with comorbidities. Despite ample evidence for disease-specific care management programs, the evidence for multimorbidity care management is limited. The review described in this article yielded one study of traditional care management and two of collaborative care programs that simultaneously targeted medical and psychiatric outcomes.

Given the relative dearth of literature on multimorbidity care management, the authors supplemented their review by outlining the pillars of effective care management, which include measurement-based care, motivational interviewing, and care coordination. They also made recommendations regarding specific interventions that could be offered based on an individual's psychiatric diagnosis and illness severity.

As the recommendations outlined here were originally intended to enhance an existing insurance-based care management program, the suggested interventions were limited to what could reasonably be offered by care managers who might not be directly embedded in a patient's primary care team.

Future studies should focus on how to effectively implement and disseminate the core features of existing multimorbidity care management models. They should also build upon prior mental health-focused studies examining which components of the interventions cited earlier offer the greatest value, in what contexts, and for which sub-populations. 20 , 25 Finally, they should evaluate the relative impact of care management programs for individuals with comorbid medical and psychiatric conditions as compared with the direct provision of mental health services in the primary care setting (ie, integrated care). Only once these questions are answered will we truly be able to make progress on providing equitable, high-quality care to individuals with medical and psychiatric comorbidities.

Acknowledgments

The authors wish to thank Nick Patel, PharmD, PhD, for his important role in liaising between Humana, Inc. and Cambridge Health Alliance.

Author Disclosure Statement

Ms. Holland reports employment with Humana, Inc. Dr. Ruble and Dr. Parsons report employment and equity holdings with Humana, Inc. All other authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

Funding Information

This study was supported by funding from Humana, Inc. (grant number 1971660). The sponsors were involved in study design and article review. The sponsors had no role in the conduct of the study, including data collection, management, analysis, and interpretation, or the decision to submit the article for publication.

Assessment of Intellectual Disabilities (ID) and Comorbid Disorders in Children

First Online: 11 June 2023

Cite this chapter

Mark R. McGowan 3 &
Jenna M. Hennessey 3

Part of the book series: Autism and Child Psychopathology Series ((ACPS))

1902 Accesses

The purpose of this chapter is to provide an overview of the multimethod, multisource approach that is typically employed when completing a comprehensive assessment of children and adolescents with an intellectual disability (ID) who may present with comorbid disorders. Current diagnostic practice guidelines emphasize the importance of assessing intellectual ability and adaptive functioning to establish a diagnosis of ID, while also taking into consideration possible comorbid mental, emotional, and behavioral disorders (American Psychiatric Association [APA], 2013). This chapter will review assessment measures used to evaluate cognitive, adaptive, social, emotional, and behavioral functioning in youth suspected of having an intellectual disability. Attention is given to the modifications and adaptations that may need to be considered when assessing youth with comorbid conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Get 10 units per month
Download Article/Chapter or Ebook
1 Unit = 1 Article or 1 Chapter
Cancel anytime
Available as PDF
Read on any device
Instant download
Own it forever
Available as EPUB and PDF
Compact, lightweight edition
Free shipping worldwide - see info
Durable hardcover edition
Dispatched in 3 to 5 business days

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Assessment of Intellectual Disabilities: Considerations for Dual Diagnosis

Psychiatric Disorders in Children and Adolescents with Intellectual Disability

Intellectual Disabilities

Achenbach, T. M. (2001). Manual for the ASEBA school-age forms and profiles . Research Center for Children, Youth, and Families.

Google Scholar

Achenbach, T. M., McConaughy, S. H., & Howell, C. T. (1987). Child/adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychological Bulletin, 101 , 213–232.

PubMed Google Scholar

Aman, M. G., & Singh, N. N. (1986). Aberrant behavior checklist manual . Slosson Educational Publications.

Aman, M. G., Tassé, M. J., Rojahn, J., & Hammer, D. (1996). The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities, 17 , 41–57.

American Academy of Pediatrics. (2014). Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics, 134 , 903–918. https://doi.org/10.1542/peds.2014-1839

Article Google Scholar

American Academy of Pediatrics. (2018). Intellectual disabilities. Pediatrics, 39 , 299–309. https://doi.org/10.1542/pir.2016-0116

American Psychiatric Association. (2013). Diagnostic and statistical manual for mental disorders (5th ed.). American Psychiatric Publishing.

Armstrong, K. H., Hangauer, J., Agazzi, H., Nunez, A., & Gieron-Korthals, M. (2013). Psychopathology of intellectual and developmental disabilities. In A. Davis (Ed.), Psychopathology of childhood and adolescence: A neuropsychological approach (pp. 27–44). Springer Publishing Co.

Baker, B. L., McIntyre, L. L., Blacher, J., Crnic, K., Edelbrock, C., & Low, C. (2003). Pre-school children with and without developmental delay: Behaviour problems and parenting stress over time. Journal of Intellectual Disability Research, 47 (4–5), 217–230.

Baker, J. K., Fenning, R. M., Crnic, K. A., Baker, B. L., & Blacher, J. (2007). Prediction of social skills in 6-year-old children with and without developmental delays: Contributions of early regulation and maternal scaffolding. American Journal on Mental Retardation, 112 (5), 375–391.

Bamburg, J. W., Cherry, K. E., Matson, J. L., & Penn, D. (2001). Assessment of schizophrenia in persons with severe and profound mental retardation using the Diagnostic Assessment for the Severely Handicapped-II (DASH-II). Journal of Developmental and Physical Disabilities, 13 (4), 319–331.

Beck, A. T., & Steer, R. A. (1988). Manual for Beck hopelessness scale . Psychological Corporation.

Beck, A. T., & Steer, R. A. (1993). Manual for the Beck anxiety inventory . Psychological Corporation.

Beck, A. T., Steer, R. A., & Ranieri, W. F. (1988). Scale for suicide ideation – Psychometric properties of a self-report version. Journal of Clinical Psychology, 44 (4), 499–505.

Beck, A. T., Steer, R. A., & Brown, G. K. (1996). Beck depression inventory (2nd ed.). The Psychological Corporation.

Beck, J. S., Beck, A. T., Jolly, J. B., & Steer, R. A. (2005). Beck youth inventories second edition for children and adolescents manual . PsychCorp.

Ben Itzchack, E., Lahat, E., Burgin, R., & Zachor, A. D. (2008). Cognitive, behavior, and intervention outcome in young children with autism. Research in Developmental Disabilities, 29 , 447–458.

Ben-Porath, Y. S., & Tellegen, A. (2020). Minnesota Multiphasic Personality Inventory-3 (MMPI-3): Manual for administration, scoring, and interpretation . University of Minnesota Press.

Boucher, J., Bigham, S., Mayes, A., & Muskett, T. (2008). Recognition and language in low functioning autism. Journal of Autism and Developmental Disorders, 38 , 1259–1269.

Boydell, K. M., Hodgins, M., Pignatiello, A., Teshima, J., Edwards, H., & Willis, D. (2014). Using technology to deliver mental health services to children and youth: A coping review. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 23 , 87–99.

PubMed PubMed Central Google Scholar

Bracken, B. A., & McCallum, R. S. (2016a). Universal nonverbal intelligence test, second edition . Pro-Ed.

Bracken, B. A., & McCallum, R. S. (2016b). Examiner’s manual universal nonverbal intelligence test, second edition . Pro-Ed.

Brady, R. P. (2011). Picture interest career survey, second edition: Administrator’s guide . JIST Publishing.

Brearly, T. W., Shura, R. D., Martindale, S. L., Lazowski, R. A., Luxton, D. D., Shenal, B. V., & Rowland, J. A. (2017). Neuropsychological test administration by videoconference: A systematic review and meta-analysis. Neuropsychology Review, 27 , 174–186.

Brigance, A. H. (2010). Brigance: Transition skills inventory . Curriculum Associates, Inc.

Brown, L., Sherbenov, R. J., & Johnsen, S. K. (2010a). Test of nonverbal intelligence, fourth edition . Pro-Ed.

Brown, L., Sherbenov, R. J., & Johnsen, S. K. (2010b). Examiner’s manual test of nonverbal intelligence, fourth edition . Pro-Ed.

Bruininks, R. H., Woodcock, R. W., Weatherman, R. F., & Hill, B. K. (1996). Comprehensive manual scales of independent behavior-revised . Riverside Publishing.

Buntinx, W. H. E., & Schalock, R. L. (2010). Models of disability, quality of life, and individualized supports: Implications for professional practice in intellectual disability. Journal of Policy and Practice in Intellectual Disabilities, 7 , 283–294. https://doi.org/10.1111/j.1741-1130.2010.00278.x

Butcher, J. N., Williams, C. L., Graham, J. R., Archer, R. P., Tellegen, A., Ben-Porath, Y. S., & Kaemmer, B. (1992). Minnesota Multiphasic Personality Inventory-Adolescent Version(MMPI-A): Manual for administration, scoring and interpretation . University of Minnesota Press.

Campbell, J. M., & Hammond, R. K. (2014). Best practices in rating scale assessment of children’s behavior. In P. Harrison & A. Thomas (Eds.), Best practices in school psychology: Data-based and collaborative decision making (pp. 287–304). National Association of School Psychologists.

Campbell, D. P., Hyne, S. A., & Nilsen, D. L. (1992). Manual for the Campbell interest and skill survey . National Computer Systems.

Cheney, D. (2012). Transition tips for educators working with students with emotional and behavioral disabilities. Intervention in School and Clinic, 48 (1), 22–29.

Christ, T. J., & Aranas, Y. A. (2014). Best practices in problem analysis. In P. Harrison & A. Thomas (Eds.), Best practices in school psychology: Data-based and collaborative decision making (pp. 87–97). National Association of School Psychologists.

Clark, G. M., & Patton, J. R. (2004). Transition planning inventory: Computer version . PRO-ED.

Clark, S. W., Gulin, S. L., Heller, M. B., & Vrana, S. R. (2017). Graduate training implications of the q-interactive platform for administering Wechsler intelligence tests. Training and Education in Professional Psychology, 11 (3), 148–155.

Daniel, M. H. (2012). Equivalence of q-interactive administered cognitive tasks: cvlt-ii and selected d-kefs subtests . Retrieved from https://www.helloq.com/content/dam/ped/ani/us/helloq/media/Technical%20Report%203_CVLT_DKEFS_final_rev.pdf

Daniel, M. H. (2013a). User survey on Q-interactive examinee behavior . Pearson.

Daniel, M. H. (2013b). Equivalence of q-interactive and paper administrations of cognitive tasks: Selected NEPSY-II and CMS subtests . Retrieved from https://www.helloq.com/content/dam/ped/ani/us/helloq/media/Technical%20Report%204_NEPSY-II_CMS.pdf

Daniel, M. H. (2013c). Equivalence of q-interactive and paper administrations of the WMS-IV cognitive tasks . Retrieved from https://www.helloq.com/content/dam/ped/ani/us/helloq/media/Technical_Report_6_WMS-IV.pdf

Daniel, M. H. (2013d) Equivalence of q-interactive and paper scoring of academic tasks: Selected WIAT-III subtests . Retrieved from https://www.helloq.com/content/dam/ped/ani/us/helloq/media/Technical-Report-5-WIAT-III.pdf

Daniel, M. H., & Wahlstrom, D. (2019). Raw-score equivalence of computer-assisted and paper version of WISC-V. Psychological Services, 16 , 213–220. https://doi.org/10.1037/ser0000295

Article PubMed Google Scholar

Daniel, M. H., Wahlstrom, D., & Zhang, O. (2014). Equivalence of Q-interactive and paper administration of cognitive tasks: WISC-V . Retrieved from https://www.pearsonassessments.com/content/dam/school/global/clinical /us/assets/wisc-v/q- interactive-wisc-v.pdf

Daniel, M. H., Wahlstrom, D., & Zhang, O. (2014a). Equivalence of q-interactive and paper administrations of cognitive tasks: Wisc-v q-interactive technical report . Retrieved from http://www.helloq.com/content/dam/ped/ani/us/helloq/media/Technical-Report_WISC-V_092514.pdf

de Bildt, A., Serra, M., Kraijer, D., Sytema, S., & Minderaa, R. (2005). Social skills in children with intellectual disabilities with and without Autism. Journal of Intellectual Disability Research, 49 , 317–328.

Deb, S., Dhaliwal, A.-J., & Roy, M. (2008). The usefulness of Conners’ Rating Scales-Revised in screening for attention deficit hyperactivity disorder in children with intellectual disabilities and borderline intelligence. Journal of Intellectual Disability Research, 52 (11), 950–965.

Dekker, M. C., & Koot, H. M. (2003). DSM-IV disorders in children with borderline to moderate intellectual disability. I: Prevalence and impact. Journal of the American Academy of Child & Adolescent Psychiatry, 42 , 915–922.

Delis, D. C., Kramer, J. H., Kaplan, E., Ober, B. A., & Fridlund, A. J. (1994). California verbal learning test children’s version . The Psychological Corporation.

Delis, D. C., Kaplan, E., & Kramer, J. H. (2001). Delis Kaplan executive function system . The Psychological Corporation.

Delis, D. C., Kramer, J. H., Kaplan, E., & Ober, B. A. (2017). California verbal learning test–3. Third . The Psychological Corporation.

Derogatis, L. R., & Lazarus, L. (1994). SCL-90—R, Brief Symptom Inventory, and matching clinical rating scales. In M. E. Maruish (Ed.), The use of psychological testing for treatment planning and outcome assessment (pp. 217–248). Lawrence Erlbaum Associates, Inc.

Derogatis, L. R., & Spencer, M. S. (1982). The Brief Symptom Inventory (BSI) administration, scoring, and procedures manual-I . Johns Hopkins University School of Medicine, Clinical Psychometrics Research Unit.

Douma, J. C. H., Dekker, M. C., Verhulst, F. C., & Koot, H. M. (2006). Self-reports on mental health problems of youth with moderate to borderline intellectual disabilities. Journal of the American Academy of Child and Adolescent Psychiatry, 45 (10), 1224–1231.

Dunn, D. M. (2018). Peabody picture vocabulary test fifth edition . NCS Pearson, Inc.

Eifeld, S. L., Piccinin, A. M., Mackinnon, A., Hofer, S. M., Taffe, J., Gray, K. M., et al. (2006). Psychopathology in young people with intellectual disability. Journal of the American Medical Association, 296 , 1981–1989.

Elford, R., White, H., Bowering, R., Ghandi, A., Maddiggan, B., St John, K., et al. (2000). A randomized, controlled trial of child psychiatric assessments conducted using videoconferencing. Journal of Telemedicine and Telecare, 6 , 73–82. https://doi.org/10.1258/1357633001935086 . Assessment, Inc.

Elliott, C. D. (2007). Introductory and technical handbook differential ability scales, second edition . Harcourt Assessment, Inc.

Embregts, P. J. C. M. (2000). Reliability of the child behavior checklist for the assessment of behavioral problems of children and youth with mild mental retardation. Research in Developmental Disabilities, 21 (1), 31–41.

Emerson, E. (2005). Use of the Strengths and Difficulties Questionnaire to assess the mental health needs of children and adolescents with intellectual disabilities. Journal of Intellectual and Developmental Disability, 30 (1), 14–23.

Farmer, C., & Aman, M. (2009). Development of the Children’s Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP). Research in Developmental Disabilities, 30 , 1155–1167.

Flanagan, D. P., Ortiz, S. O., & Alfonso, V. C. (2013). Essentials of cross-battery assessment, third edition . Wiley.

Freeman, N. C., Gray, K. M., Taffe, J. R., & Cornish, K. M. (2015). Development of a new attention rating scale for children with intellectual disability: The scale of attention in intellectual disability (SAID). American Journal on Intellectual and Developmental Disabilities, 120 , 91–109. https://doi.org/10.1352/1944-7558-120.2.91

Gardner, W. I., & Hunter, R. H. (2003). Psychosocial diagnosis and treatment services in inpatient psychiatric facilities for persons with mental retardation: Practice guides. Mental Health Aspects of Developmental Disabilities, 6 , 68–80.

Gilbert, K., Kranzler, J. H., & Benson, N. (2021). An independent examination of the equivalence of the standard and digital administration formats of the Wechsler Intelligence Scale for Children-5th Edition. Journal of School Psychology, 85 , 113–124. https://doi.org/10.1016/j.jsp.2021.01.002

Gray, K., Tonge, B., Einfeld, S., Gruber, C., & Klein, A. (2018). Manual for the developmental behavior checklist 2 . WPS.

Gresham, F. M., & Elliott, S. N. (2008). Social skills improvement system rating scales manual . NCS Pearson.

Hahn, L. J., Brady, N. C., Warren, S. F., & Fleming, K. K. (2015). Do children with Fragile X syndrome show declines or plateaus in adaptive behavior? American Journal on Intellectual and Developmental Disabilities, 120 , 412–432.

Haley, S., & Coster, W. (2010). PEDI-CAT: Development, standardization and administration manual . CRECare, LLC.

Hammill, D. D., Pearson, N. A., & Wiederholt, J. L. (2009a). Comprehensive test of nonverbal intelligence, second edition . Pro-Ed.

Hammill, D. D., Pearson, N. A., & Wiederholt, J. L. (2009b). Examiner’s manual comprehensive test of nonverbal intelligence, second edition . Pro-Ed.

Hardiman, S., Guerin, S., & Fitzsimons, E. (2009). A comparison of the social competence of children with moderate intellectual disability in inclusive versus segregated school settings. Research in Developmental Disabilities, 30 (2), 397–407.

Harrison, P. L., & Oakland, T. O. (2015). Manual adaptive behavior assessment system, third edition . Western Psychological Services.

Hartman, C. A., Luteijn, E., Serra, M., & Minderaa, R. B. (2006). Refinement of the Children’s social behavior questionnaire (CSBQ): An instrument that describes the diverse problems seen in milder forms of PDD. Journal of Autism and Developmental Disorders, 36 , 325–342.

Hennessey, J. M., & McGowan, M. R. (2020). Effects of I.Q. and adaptive behavior on assessment and treatment of dual diagnosis. In J. L. Matson (Ed.), Handbook of dual diagnosis: Assessment and treatment in persons with intellectual abilities (pp. 77–94). Springer. https://doi.org/10.1007/978-3-030-46835-4

Chapter Google Scholar

Hoffman, A., Hoffman, S. F., & Sawilowsky, S. (2015). Self-determination assessment internet user’s manual . Early Education Group, Inc.

Holden, B., & Gitlesen, J. P. (2004). The association between psychiatric symptoms in adults with mental retardation and challenging behavior. Research in Developmental Disabilities, 24 , 323–332.

Horn, E., & Fuchs, D. (1987). Using adaptive behavior in assessment and intervention: An overview. The Journal of Special Education, 21 , 11–26.

Individuals With Disabilities Education Act, 20 U.S.C. § 1400 (2004).

Johansson, C. B. (2003). Career assessment inventory: The enhanced version manual (Rev. ed.). National Computer Systems.

Johnson, C. P., Walker, W. O., Palomo-Gonzalez, S. A., & Curry, C. J. (2006). Mental retardation: Diagnosis, management, and family support. Current Problems in Pediatric and Adolescent Health Care, 36 , 126–165. https://doi.org/10.1016/j.cppeds.2005.11.005

Kaufman, A. S., & Kaufman, N. L. (2004a). Kaufman assessment battery for children (2nd ed.). Pearson.

Kaufman, A. S., & Kaufman, N. L. (2004b). Manual Kaufman assessment battery for children (2nd ed.). Pearson.

Kohler, P. D., & Field, S. (2003). Transition-focused education: Foundation for the future. The Journal of Special Education, 37 (3), 174–183.

Korkman, M., Kirk, U., & Kemp, S. (1998). NESPY: A developmental neuropsychological assessment . The Psychological Corporation.

Kozlowski, A. M., Matson, J. L., Sipes, M., Hattier, M. A., & Bamburg, J. W. (2011). The relationship between psychopathology symptom clusters and the presence of comorbid psychopathology in individuals with severe to profound intellectual disability. Research in Developmental Disabilities, 32 , 1610–1614.

Kraijer, D. W. (2006). Pervasive developmental disorder in mental retardation scale manual: Second revised edition (PITS B.V). Psychologische Instrumenten Tests EnServices.

Lambert, N., Nihira, K., & Leland, H. (1993). Examiner’s manual adaptive behavior scale-school, second edition . Pro-Ed.

Lecavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36 , 1101–1114. https://doi.org/10.1007/s10803-004-5291-1

Levinson, E. M., & Palmer, E. J. (2005). Preparing students with disabilities for school-to-work transition and postschool life. Principal Leadership, 5 , 11–15.

LoVullo, S. V., & Matson, J. L. (2009). Comorbid psychopathology in adults with Autism Spectrum Disorders and intellectual disabilities. Research in Developmental Disabilities, 30 , 1288–1296.

Luckasson, R., & Schalock, R. L. (2013). Defining and applying a functionality approach to intellectual disability. Journal of Intellectual Disability Research, 57 , 657–668.

Luckasson, R., & Schalock, R. L. (2015). Standards to guide the use of clinical judgment in the field of intellectual disability. Intellectual and Developmental Disabilities, 53 , 240–251. https://doi.org/10.1352/1934-9556-53.3.240

Magyar, C. I., Pandolfi, V., & Dill, C. A. (2012). An initial evaluation of the social communication questionnaire for the assessment of autism spectrum disorders in children with down syndrome. Journal of Developmental & Behavioral Pediatrics, 33 , 134–145. https://doi.org/10.1097/dbp.0b013e318240d3d9

Martin, N., & Brownell, R. (2005). Test of auditory processing skills (3rd ed.). Academic Therapy Publications.

Martin, R. P., Hooper, S., & Snow, J. (1986). Behavior rating scale approaches to personality assessment in children and adolescents. In H. Knoff (Ed.), The assessment of child and adolescent personality (pp. 309–351). Guilford.

Mash, E. J., & Barkley, R. A. (2007). Assessment of childhood disorders (4th ed.). Guilford Press.

Mather, N., & Wendling, B. J. (2014). Examiner’s manual Woodcock-Johnson IV tests of cognitive abilities . Riverside.

Matson, J., & Scior, K. (2004). “Diagnostic overshadowing” amongst clinicians working with people with intellectual disabilities in the UK. Journal of Applied Research in Intellectual Disabilities, 17 , 85–90.

Matson, J. L., & Shoemaker, M. (2009). Intellectual disability and its relationship to autism spectrum disorder. Research in Developmental Disabilities, 30 , 1107–1114.

Matson, J. L., Bamburg, J. W., Cherry, K. E., & Paclawskyj, T. R. (1999a). A validity study on the Questions About Behavioral Function (QABF) scale: Predicting treatment success for self-injury, aggression, and stereotypies. Research in Developmental Disabilities, 20 (2), 163–175.

Matson, J. L., Bamburg, J. W., & Mayville, E. A. (1999b). Seizure disorder in people with intellectual disability: An analysis of difference in social functioning, adaptive functioning and maladaptive behaviors. Journal of Intellectual Disability Research, 43 , 531–539.

Matson, J. L., Kuhn, D. E., Dixon, D. R., Mayville, S. B., Laud, R. B., Cooper, C. L., Malone, C. J., Minshawi, N. F., Singh, A. N., Stewart, H. A., Luke, M. A., & Matson, M. L. (2003a). The development and factor structure of the functional assessment for multiple CausaliTy (FACT). Research in Developmental Disabilities, 24 , 485–495. https://doi.org/10.1016/j.ridd.2003.07.001

Matson, J. L., Mayville, E. A., Lott, J. D., Bielecki, J., & Logan, R. (2003b). A comparison of social and adaptive functioning in person with psychosis, autism, and severe or profound mental retardation. Journal of Developmental and Physical Disabilities, 15 , 57–65.

Matson, J. L., Dempsey, T., & Fodstad, J. C. (2009a). The effect of autism spectrum disorders on adaptive independent living skills in adults with severe intellectual disability. Research in Developmental Disabilities, 30 , 603–611.

Matson, J. L., Rivet, T. T., Fodstad, J. C., Dempsey, T., & Boisjoli, J. A. (2009b). Examination of adaptive behavior differences in adults with autism spectrum disorders and intellectual disability. Research in Developmental Disabilities, 30 , 1317–1325.

Matson, J. L., Horovitz, M., & Sipes, M. (2010). Characteristics of individuals with toileting problems and intellectual disability using the Profile of Toileting Issues (POTI). Journal of Mental Healthy Research in Intellectual Disabilities, 4 , 53–63. https://doi.org/10.1080/19315864.2010.531443

McCarney, S., & Arthaud, T. J. (2013). Attention deficit disorders evaluation scale, 4th edition . Hawthorne Educational Services.

McConaughy, S. H., & Ritter, D. R. (2014). Best practices in mulimethod assessment of emotional and behavioral disorders. In P. Harrison & A. Thomas (Eds.), Best practices in school psychology: Data-based and collaborative decision making (pp. 367–390). National Association of School Psychologists.

Medeiros, K., Rojahn, J., Moore, L. L., & van Ingen, D. J. (2014). Functional properties of behavior problems depending on level of intellectual disability: Functions of behavior problems by ID. Journal of Intellectual Disability Research, 58 , 151–161. https://doi.org/10.1111/jir.12025

Merrell, K., & Walker, H. (2004). Deconstructing a definition: Social maladjustment versus emotional disturbance and moving the EBD field forward. Psychology in the Schools, 41 (8), 899–910.

Miller, M. L., Fee, V. E., & Jones, C. J. (2004). Psychometric properties of ADHD rating scales among children with mental retardation II: Validity. Research in Developmental Disabilities, 25 (5), 477–492.

Millon, T., Green, C. J., & Meagher, R. B. J. R. (1982). Millon adolescent personality inventory manual . National Computer Systems.

Millon, T., Millon, C., & Davis, R. (1993). Millon adolescent clinical inventory manual . National Computer Systems.

Millon, T., Tringone, R., Millon, C., & Grossman, S. (2005). Millon pre-adolescent clinical inventory manual . Pearson.

Millon, T., Grossman, S., & Millon, C. (2015). Millon clinical multiaxial inventory-IV manual . Pearson.

Minjarez, M., Phillips, J. M., Feinstein, C., & Hardan, A. Y. (2011). Psychiatric disorders in individuals with intellectual disabilities. In H. Steiner (Ed.), Handbook of developmental psychiatry (pp. 491–522). World Scientific.

Moss, S., Emerson, E., Kiernan, C., Turner, S., Hatton, C., & Alborz, A. (2000). Psychiatric symptoms in adults with learning disability and challenging behaviour. British Journal of Psychiatry, 177 , 452–456.

Munson, J., Dawson, G., Sterling, L., Beauchaine, T., Zhou, A., & Koehler, E. (2008). Evidence for latent classes of IQ in young children with autism spectrum disorder. American Journal on Mental Retardation, 113 , 439–452.

Myers, K. M., Valentine, J. M., & Melzer, S. M. (2008). Child and adolescent telepsychiatry: Utilization and satisfaction. Telemedicine Journal and E-Health, 14 , 131–137. https://doi.org/10.1089/tmj.2007.0035

Myrbakk, E., & von Tetzchner, S. (2008). Psychiatric disorders and behavior problems in people with intellectual disability. Research in Developmental Disabilities, 29 , 316–332. https://doi.org/10.1016/j.ridd.2007.06.002

O’Brien, G., & Pearson, J. (2004). Autism and learning disability. Autism, 8 , 125–140.

Peters-Scheffer, N., Didden, R., Green, V. A., Sigafoos, J., Korzilius, H., Pituch, K., O’Reilly, M. F., & Lancioni, G. (2008). The behavior flexibility rating scale-revised (BFRS-R): Factor analysis, internal consistency, inter-rater and intra-rater reliability, and convergent validity. Research in Developmental Disabilities, 29 , 398–407. https://doi.org/10.1016/j.ridd.2007.07.004

Raiford, S. E., Zhang, O., Whipple Drozdick, L., Getz, K., Wahlstrom, D., Gabel, A., Holdnack, J. A., & Daniel, M. (2016). WISC-V coding and symbol search in digital format: Reliability, validity, special group studies, and interpretation . Pearson. Retrieved from https://images.pearsonclinical.com/images/Assets/WISC-V/Qi-Processing-Speed-Tech-Report.pdf

Randolph, C. (2009). RBANS update: Repeatable battery for the assessment of neuropsychological status: Manual . Pearson.

Reddy, L. (2001). Serious emotional disturbance in children and adolescents: Current status and future directions. Behavior Therapy, 32 , 667–691.

Reed, G. M., McLaughlin, C. J., & Milholland, K. (2000). Ten interdisciplinary principles for professional practice in telehealth: Implications for psychology. Professional Psychology, Research and Practice, 31 , 170–178. https://doi.org/10.1037/0735-7028.31.2.170

Reiss, S. (1988). Test manual for the Reiss Screen for maladaptive behavior . International Diagnostic Systems.

Reiss, S., & Valenti-Hein, D. (1994). Development of a psychopathology rating scale for children with mental retardation. Journal of Consulting and Clinical Psychology, 62 , 28–33. https://doi.org/10.1037/0022-006x62.1.28

Reynolds, C. R., & Kamphaus, R. W. (2015). Behavior assessment system for children, third edition . Pearson Clinical.

Roid, G. H. (2003a). Stanford-Binet intelligence scales, fifth edition . Riverside Publishing.

Roid, G. H. (2003b). Examiner’s manual Stanford-Binet intelligence scales, fifth edition . Riverside Publishing.

Roid, G. H., Miller, L. J., Pomplun, M., & Koch, C. (2013a). Leiter international performance scale-third edition . Stoelting Company.

Roid, G. H., Miller, L. J., Pomplun, M., & Koch, C. (2013b). Manual Leiter international performance scale-third edition . Stoelting Company.

Rojahn, J., Matson, J. L., Naglieri, J. A., & Mayville, E. (2004). Relationships between psychiatric conditions and behavior problems among adults with mental retardation. American Journal on Mental Retardation, 109 , 21–33.

Rojahn, J., Rowe, E. W., Sharber, A. C., Hastings, R., Matson, J. L., Didden, R., Kroes, D. B. H., & Dumont, E. L. M. (2012). The behavior problems inventory-short form for individuals with intellectual disabilities: Part I: Development and provisional clinical reference data. Journal of Intellectual Disability Research, 56 , 527–545. https://doi.org/10.1111/j.1365-2788.2011.01507.x

Rush, K. S., Bowman, L. G., Eidman, S. L., Toole, L. M., & Mortenson, B. P. (2004). Assessing psychopathology in individual with developmental disabilities. Behavior Modification, 28 , 621–637. https://doi.org/10.1177/0145445503259830

Sattler, J. M. (2007). Assessment of children: Cognition foundations (5th ed.). Jerome M. Sattler Publisher, Inc.

Schalock, R. L., & Luckasson, R. (2015). A systematic approach to subgroup classification in intellectual disability. Intellectual and Developmental Disabilities, 53 , 358–366.

Schalock, R. L., Borthwick-Duffy, S. A., Bradley, V. J., Buntinx, W. H. E., Coulter, D. L., Craig, E. M., Gomez, S. C., Lachapelle, Y., Luckasson, R., Reeve, A., Shogren, K. A., Snell, M. E., Spreat, S., Tassé, M. J., Thompson, J. R., Verdugo-Alonso, M. A., Wehmeyer, M. L., & Yeager, M. H. (2010). Intellectual disability: Definition, classification and systems of supports (11th ed.). American Association on Intellectual and Developmental Disabilities.

Schrank, F. A., McGrew, K. S., & Mather, N. (2014). Woodcock-Johnson IV tests of cognitive abilities . Riverside.

Seo, H., Wehmeyer, M. L., Shogren, K. A., Hughes, C., Thompson, J. R., Little, T. D., & Palmer, S. B. (2017). Examining underlying relationships between the supports inventory scale-adult version and the supports intensity scale-children’s version. Assessment for Effective Intervention, 42 , 237–247. https://doi.org/10.1177/15344508417705084

Shapiro, E. S., & Kratochwill, T. R. (Eds.). (2000). Behavioral assessment in schools: Theory, research, and clinical foundations (2nd ed.). The Guilford Press.

Shevell, M. (2008). Global developmental delay and mental retardation or intellectual disability: Conceptualization, evaluation, and etiology. Pediatric Clinics of North America, 55 , 1–6.

Shogren, K. A., & Plotner, A. J. (2012). Transition planning for students with intellectual disability, autism, or other disabilities: Data from the national longitudinal transition study-2. Intellectual Developmental Disabilities, 50 (1), 16–30.

Siperstein, G. N., Parker, R. C., & Drascher, M. (2013). National snapshot of adults with intellectual disabilities in the labor force. Journal of Vocational Rehabilitiation, 39 , 157–165. https://doi.org/10.3233/JVR-130658

Smith, K. R., & Matson, J. L. (2010). Psychopathology: Differences among adults with intellectually disabled, comorbid autism spectrum disorders and epilepsy. Research in Developmental Disabilities, 31 , 743–749.

Sparrow, S. S., Cicchetti, D. V., & Saulnier, C. A. (2016). Manual Vineland adaptive behavioral scales, third edition . PsychCorp.

Srivastava, A. K., & Schwartz, C. E. (2014). Intellectual disability and autism spectrum disorders: Causal genes and molecular mechanisms. Neuroscience & Biobehavioral Reviews, 46 , 161–174. https://doi.org/10.1016/j.neubiorev.2014.02.015

Srour, M., & Shevell, M. (2014). Genetics and the investigation of developmental delay/intellectual disability. Archives of Disease in Childhood, 99 , 386–389. https://doi.org/10.1136/archdischild-2013-304063

Stage, S. A., Jackson, H. G., Moscovitz, K., Erickson, M. J., Thurman, S. O., Jessee, W., & Olsen, E. M. (2006). Using multimethod-multisource functional behavioral assessment for students with behavioral disabilities. School Psychology Review, 35 , 451–471. https://doi.org/10.1080/02796015.2006.12087978

Steege, M. W., Pratt, J. L., Wickerd, G., Guare, R., Watson, T. S., & Gresham, F. M. (2019). Conducting school-based functional behavioral assessments: A practitioner’s guide (3rd ed.). Gilford Press.

Stratis, E. A., & Lecavalier, L. (2015). Informant agreement for youth with autism spectrum disorder or intellectual disability: A meta-analysis. Journal of Autism and Developmental Disorders, 45 , 1026–1041. https://doi.org/10.1007/s10803-014-2258-8

Tassé, M. J., Aman, M. G., Hammer, D., & Rojahn, J. (1996). The Nisonger child behavior rating form: Age and gender effects and norms. Research in Developmental Disabilities, 17 , 59–75.

Tassé, M. J., Schalock, R. L., Balboni, G., Bersani, H. A., Jr., Borthwick-Duffy, S. A. S., Spreat, et al. (2012). The construct of adaptive behavior: Its conceptualization, measurement, and use in the filed of intellectual disability. American Journal on Intellectual and Developmental Disabilities, 117 , 291–303.

Tassé, M. J., Luckasson, R., & Schalock, R. L. (2016). The relation between intellectual functioning and adaptive behavior in the diagnosis of intellectual disability. Intellectual and Developmental Disabilities, 54 , 381–390.

Thompson, J. R., Wehmeyer, M. L., Hughes, C., Shogren, K. A., Palmer, S., & Seo, H. (2014). The supports intensity scale –Children’s version: Preliminary reliability and validity. Inc, 2 (2), 140–219.

Thompson, J. R., Wehmeyer, M. L., Hughes, C., Shogren, K. A., Seo, H., Little, T. D., & Schalock, R. L. (2016). Supports intensity scale-Children’s version . American Association on Intellectual and Developmental Disabilities.

Toth, K., deLacy, N., & King, B. H. (2015). Intellectual disability. In M. K. Dulcan (Ed.), Dulcan’s textbook of child and adolescent psychiatry, second edition . APA.

Tremblay, K. N., Richer, L., Lachance, L., & Cote, A. (2010). Psychopathological manifestations of children with intellectual disabilities according to their cognitive and adaptive behavior profile. Research in Developmental Disabilities, 31 , 57–69.

Tureck, K., Matson, J. L., Cervantes, P., & Konst, M. J. (2014). An examination of the relationship between autism spectrum disorder, intellectual functioning, and comorbid symptoms in children. Research in Developmental Disabilities, 35 , 1766–1772.

Turygin, N. C., Matson, J. L., & Adams, H. L. (2014a). Prevalence of co-occurring disorders in a sample of adults with mild and moderate intellectual disabilities who reside in a residential treatment setting. Research in Developmental Disabilities, 35 , 1802–1808.

Turygin, N. C., Matson, J. L., Adams, H. L., & Williams, L. W. (2014b). Co-occurring disorder clusters in adults with mild and moderate intellectual disability in residential treatment settings. Research in Developmental Disabilities, 35 , 3156–3161.

Wagner, R. K., Torgesen, J. K., Rashotte, C. A., & Pearson, N. A. (2013). Comprehensive test of phonological processing–second edition . PRO-ED.

Wechsler, D. (2008). WAIS-IV administration and scoring manual . The Psychological Corporation.

Wechsler, D. (2009). Wechsler memory scales – Fourth edition (WMS-IV): Administration and scoring manual . Pearson Clinical Assessment.

Wechsler, D. (2012). Wechsler Preschool and Primary Scale of Intelligence–Fourth Edition (WPPSI-IV): Administration and scoring manual . The Psychological Corporation.

Wechsler, D. (2014). Wechsler intelligence scale for children (5th ed.). Pearson.

Wechsler, D., Raiford, S. E., & Holdnack, J. A. (2014). Technical and interpretive manual Wechsler intelligence scale for children, fifth edition . Pearson.

Wehman, P. (2013). Transition from school to work: Where are we and where do we need to go? Career Development and Transition for Exceptional Individuals, 36 (1), 58–66.

Wehmeyer, M. L. (1995). The Arc’s Self-Determination Scale: Procedural guidelines . Arlington, TX: The Arc of the United States.

Wehmeyer, M. L., & Kelchner, K. (1995). The Arc’s self-determination scale- adolescent version . The Arc of the United States.

Whitcomb, S. A. (2018). Behavioral, social, and emotional assessment of children and adolescents (5th ed.). NewYork, NY: Routledge.

Wiig, E. H., Semel, E., & Secord, W. A. (2013). Clinical evaluation of language fundamentals–Fifth edition (CELF-5) . NCS Pearson.

Wilkins, J., & Matson, J. L. (2009). A comparison of social skills profiles in intellectually disabled adults with and without ASD. Behavior Modification, 33 , 143–155.

Williams, K. T. (2018). Expressive vocabulary test third edition . NCS Pearson, Inc.

Witwer, A. N., Lawton, K., & Aman, M. G. (2014). Intellectual disability. In E. J. Mash & R. A. Barkley (Eds.), Child psychopathology (pp. 593–624). The Guilford Press.

World Health Organization. (2018). The international classification of diseases (11th ed.). Author. Retrieved on November 21, 2018 from https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f605267007

Wright, A. J. (2020). Equivalence of remote, digital administration and traditional, in-person administration of the Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V). Psychological Assessment, 32 , 809–817. https://doi.org/10.1037/pas0000939

Wright, A. J., Mihura, J. L., Pade, H., & McCord, D. M. (2020). Guidance on psychological tele- assessment during the COVID-19 crisis . Retrieved from https://www.apaservices.org/practice/reimbursement/health-codes/testing/tele-assessment-covid-19

Download references

Author information

Authors and affiliations.

Department of Psychology, Indiana University of Pennsylvania, Indiana, PA, USA

Mark R. McGowan & Jenna M. Hennessey

You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark R. McGowan .

Editor information

Editors and affiliations.

Department of Psychology, Louisiana State University, Baton Rouge, LA, USA

Johnny L. Matson

Rights and permissions

Reprints and permissions

Copyright information

About this chapter

McGowan, M.R., Hennessey, J.M. (2023). Assessment of Intellectual Disabilities (ID) and Comorbid Disorders in Children. In: Matson, J.L. (eds) Handbook of Clinical Child Psychology. Autism and Child Psychopathology Series. Springer, Cham. https://doi.org/10.1007/978-3-031-24926-6_28

Download citation

DOI : https://doi.org/10.1007/978-3-031-24926-6_28

Published : 11 June 2023

Publisher Name : Springer, Cham

Print ISBN : 978-3-031-24925-9

Online ISBN : 978-3-031-24926-6

eBook Packages : Behavioral Science and Psychology Behavioral Science and Psychology (R0)

Share this chapter

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Publish with us

Policies and ethics

Find a journal
Track your research

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Explore content
About the journal
Publish with us
Sign up for alerts
Published: 20 August 2020

Comorbid depression in medical diseases

Stefan M. Gold 1 , 2 , 3 ,
Ole Köhler-Forsberg 4 , 5 , 6 ,
Rona Moss-Morris 7 ,
Anja Mehnert 8 ,
J. Jaime Miranda 9 ,
Monika Bullinger 10 ,
Andrew Steptoe 11 ,
Mary A. Whooley 12 &
Christian Otte 1

Nature Reviews Disease Primers volume 6 , Article number: 69 ( 2020 ) Cite this article

9446 Accesses

234 Citations

197 Altmetric

Metrics details

Neuroscience
Translational research

Depression is one of the most common comorbidities of many chronic medical diseases including cancer and cardiovascular, metabolic, inflammatory and neurological disorders. Indeed, the prevalence of depression in these patient groups is often substantially higher than in the general population, and depression accounts for a substantial part of the psychosocial burden of these disorders. Many factors can contribute to the occurrence of comorbid depression, such as shared genetic factors, converging biological pathways, social factors, health behaviours and psychological factors. Diagnosis of depression in patients with a medical disorder can be particularly challenging owing to symptomatic overlap. Although pharmacological and psychological treatments can be effective, adjustments may need to be made for patients with a comorbid medical disorder. In addition, symptoms or treatments of medical disorders may interfere with the treatment of depression. Conversely, symptoms of depression may decrease adherence to treatment of both disorders. Thus, comprehensive treatment plans are necessary to optimize care.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 1 digital issues and online access to articles

92,52 € per year

only 92,52 € per issue

Buy this article

Purchase on Springer Link
Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Association of pre-existing depression with all-cause, cancer-related, and noncancer-related mortality among 5-year cancer survivors: a population-based cohort study

Major depressive disorder

Assessment of depression symptoms among cancer patients: a cross-sectional study from a developing country.

Otte, C. et al. Major depressive disorder. Nat. Rev. Dis. Prim. 2 , 16065 (2016). This paper provides a current overview of epidemiology, pathophysiology, diagnosis and management of MDD .

PubMed Google Scholar

Whiteford, H. A. et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet 382 , 1575–1586 (2013).

Google Scholar

Moussavi, S. et al. Depression, chronic diseases, and decrements in health: results from the world health surveys. Lancet 370 , 851–858 (2007). This paper describes the impact of comorbid depression on overall health in patients with medical disorders in a very large sample from 60 countries .

Puyat, J. H., Kazanjian, A., Wong, H. & Goldner, E. Comorbid chronic general health conditions and depression care: a population-based analysis. Psychiatr. Serv. 68 , 907–915 (2017).

Gonzalez, J. S. et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 31 , 2398–2403 (2008).

PubMed PubMed Central Google Scholar

Pelletier, G., Verhoef, M. J., Khatri, N. & Hagen, N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J. Neurooncol. 57 , 41–49 (2002).

Suppli, N. P. et al. Survival after early-stage breast cancer of women previously treated for depression: a nationwide Danish cohort study. J. Clin. Oncol. 35 , 334–342 (2017).

Rutledge, T., Reis, V. A., Linke, S. E., Greenberg, B. H. & Mills, P. J. Depression in heart failure. J. Am. Coll. Cardiol. 48 , 1527–1537 (2006).

Koyanagi, A. et al. Mortality in unipolar depression preceding and following chronic somatic diseases. Acta Psychiatr. Scand. 138 , 500–508 (2018).

CAS PubMed Google Scholar

Cai, W., Mueller, C., Li, Y.-J., Shen, W.-D. & Stewart, R. Post stroke depression and risk of stroke recurrence and mortality: a systematic review and meta-analysis. Ageing Res. Rev. 50 , 102–109 (2019).

Momen, N. C. et al. Association between mental disorders and subsequent medical conditions. N. Engl. J. Med. 382 , 1721–1731 (2020).

Plana-Ripoll, O. et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet 394 , 1827–1835 (2019).

Plana-Ripoll, O. et al. Changes over time in the differential mortality gap in individuals with mental disorders. JAMA Psychiatry 77 , 648–650 (2020).

Machado, M. O. et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Med. 16 , 112 (2018).

Roest, A. M. & de Jonge, P. The heart of the matter: in search of causal effects of depression on somatic diseases. BMC Med. 16 , 147 (2018).

Ferrari, A. J. et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol. Med. 43 , 471–481 (2013).

Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 , 1211–1259 (2017).

Pedersen, C. B. et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry 71 , 573–581 (2014).

Salk, R. H., Hyde, J. S. & Abramson, L. Y. Gender differences in depression in representative national samples: meta-analyses of diagnoses and symptoms. Psychol. Bull. 143 , 783–822 (2017).

Luppa, M. et al. Age- and gender-specific prevalence of depression in latest-life – systematic review and meta-analysis. J. Affect. Disord. 136 , 212–221 (2012).

Sjöberg, L. et al. Prevalence of depression: comparisons of different depression definitions in population-based samples of older adults. J. Affect. Disord. 221 , 123–131 (2017).

Walker, J. et al. The prevalence of depression in general hospital inpatients: a systematic review and meta-analysis of interview-based studies. Psychol. Med. 48 , 2285–2298 (2018). This paper gives an overview of the prevalence of depression among general medical and surgical inpatients, suggesting a prevalence high enough to make it worthwhile screening hospital inpatients for depression and initiating treatment where appropriate .

Wang, J. et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open 7 , e017173 (2017).

Mitchell, A. J. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 12 , 160–174 (2011).

Krebber, A. M. H. et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology 23 , 121–130 (2013).

Watts, S. et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 4 , e003901 (2014).

Watts, S., Prescott, P., Mason, J., McLeod, N. & Lewith, G. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 5 , e007618 (2015).

Huang, J. et al. Association between depression and brain tumor: a systematic review and meta-analysis. Oncotarget 8 , 94932–94943 (2017).

Mehnert, A. et al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J. Clin. Oncol. 32 , 3540–3546 (2014).

Secinti, E., Thompson, E. J., Richards, M. & Gaysina, D. Research review: childhood chronic physical illness and adult emotional health – a systematic review and meta-analysis. J. Child. Psychol. Psychiatry 58 , 753–769 (2017).

Freedland, K. E. et al. Prevalence of depression in hospitalized patients with congestive heart failure. Psychosom. Med. 65 , 119–128 (2003).

Brostow, D. P., Petrik, M. L., Starosta, A. J. & Waldo, S. W. Depression in patients with peripheral arterial disease: a systematic review. Eur. J. Cardiovasc. Nurs. 16 , 181–193 (2017).

Feng, L. et al. Prevalence of depression in myocardial infarction. Medicine 98 , e14596 (2019).

Doyle, F. et al. Systematic review and individual patient data meta-analysis of sex differences in depression and prognosis in persons with myocardial infarction. Psychosom. Med. 77 , 419–428 (2015).

Khaledi, M., Haghighatdoost, F., Feizi, A. & Aminorroaya, A. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol. 56 , 631–650 (2019).

Barnard, K. D., Skinner, T. C. & Peveler, R. The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review. Diabet. Med. 23 , 445–448 (2006).

Buchberger, B. et al. Symptoms of depression and anxiety in youth with type 1 diabetes: a systematic review and meta-analysis. Psychoneuroendocrinology 70 , 70–84 (2016).

Cooney, L. G., Lee, I., Sammel, M. D. & Dokras, A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. 32 , 1075–1091 (2017).

Mitchell, A. J. et al. Prevalence and predictors of post-stroke mood disorders: a meta-analysis and meta-regression of depression, anxiety and adjustment disorder. Gen. Hosp. Psychiatry 47 , 48–60 (2017).

Ayerbe, L., Ayis, S., Wolfe, C. D. A. & Rudd, A. G. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br. J. Psychiatry 202 , 14–21 (2013).

Boeschoten, R. E. et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J. Neurol. Sci. 372 , 331–341 (2017).

Marrie, R. A. et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology 85 , 1972–1979 (2015).

McKay, K. A. et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology 90 , e1316–e1323 (2018).

Binzer, S., McKay, K. A., Brenner, P., Hillert, J. & Manouchehrinia, A. Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study. Neurology 93 , e2216–e2223 (2019).

Kim, M., Kim, Y.-S., Kim, D.-H., Yang, T.-W. & Kwon, O.-Y. Major depressive disorder in epilepsy clinics: a meta-analysis. Epilepsy Behav. 84 , 56–69 (2018).

Goodarzi, Z. et al. Detecting depression in Parkinson disease. Neurology 87 , 426–437 (2016).

Chi, S. et al. The prevalence of depression in Alzheimer’s disease: a systematic review and meta-analysis. Curr. Alzheimer Res. 12 , 189–198 (2015).

Zhang, L., Fu, T., Yin, R., Zhang, Q. & Shen, B. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. BMC Psychiatry 17 , 70 (2017).

Dowlatshahi, E. A., Wakkee, M., Arends, L. R. & Nijsten, T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J. Investig. Dermatol. 134 , 1542–1551 (2014).

Matcham, F., Rayner, L., Steer, S. & Hotopf, M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology 52 , 2136–2148 (2013).

Neuendorf, R., Harding, A., Stello, N., Hanes, D. & Wahbeh, H. Depression and anxiety in patients with inflammatory bowel disease: a systematic review. J. Psychosom. Res. 87 , 70–80 (2016).

Mulugeta, A., Zhou, A., King, C. & Hyppönen, E. Association between major depressive disorder and multiple disease outcomes: a phenome-wide Mendelian randomisation study in the UK Biobank. Mol. Psychiatry 25 , 1469–1476 (2019).

Tylee, D. S. et al. Genetic correlations among psychiatric and immune-related phenotypes based on genome-wide association data. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177 , 641–657 (2018).

Tyrrell, J. et al. Using genetics to understand the causal influence of higher BMI on depression. Int. J. Epidemiol. 48 , 834–848 (2019).

Milaneschi, Y. et al. Genetic association of major depression with atypical features and obesity-related immunometabolic dysregulations. JAMA Psychiatry 74 , 1214–1225 (2017). This study clearly demonstrates a genetic link between depression and obesity and illustrates the possibility of using genetics to explore potential biological pathways connecting depression and medical disorders .

Haljas, K. et al. Bivariate genome-wide association study of depressive symptoms with type 2 diabetes and quantitative glycemic traits. Psychosom. Med. 80 , 242–251 (2018).

Samaan, Z. et al. Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population. Transl Psychiatry 5 , e618 (2015).

CAS PubMed PubMed Central Google Scholar

Clarke, T.-K. et al. Investigating shared aetiology between type 2 diabetes and major depressive disorder in a population based cohort. Am. J. Med. Genet. B Neuropsychiatr. Genet. 174 , 227–234 (2016).

Khandaker, G. M. et al. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. Mol. Psychiatry 25 , 1477–1486 (2020).

Brainstorm Consortium. et al. Analysis of shared heritability in common disorders of the brain. Science 360 , eaap8757 (2018).

Wang, J. S. et al. Examining the effect of 5-HTTLPR on depressive symptoms in postmenopausal women 1 year after initial breast cancer treatment. Support. Care Cancer 27 , 513–519 (2019).

Ogrodnik, M. et al. Obesity-induced cellular senescence drives anxiety and impairs neurogenesis. Cell Metab. 29 , 1061–1077 (2019).

Kennis, M. et al. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Mol. Psychiatry 25 , 321–338 (2019).

Otte, C., Neylan, T. C., Pipkin, S. S., Browner, W. S. & Whooley, M. A. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul study. Am. J. Psychiatry 162 , 2139–2145 (2005).

Otte, C. et al. Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul study. Biol. Psychiatry 56 , 241–247 (2004).

Enache, D., Pariante, C. M. & Mondelli, V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav. Immun. 81 , 24–40 (2019).

Köhler, C. A. et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr. Scand. 135 , 373–387 (2017).

Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B. & Khandaker, G. M. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol. Med. 49 , 1958–1970 (2019).

Orlovska-Waast, S. et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Mol. Psychiatry 24 , 869–887 (2018).

Hodes, G. E., Kana, V., Menard, C., Merad, M. & Russo, S. J. Neuroimmune mechanisms of depression. Nat. Neurosci. 18 , 1386–1393 (2015).

Nerurkar, L., Siebert, S., McInnes, I. B. & Cavanagh, J. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry 6 , 164–173 (2019).

Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B. & Khandaker, G. M. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry 23 , 335–343 (2016).

Wittenberg, G. M. et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol. Psychiatry 25 , 1275–1285 (2019).

Duivis, H. E. et al. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the Heart and Soul study. Am. J. Psychiatry 168 , 913–920 (2011).

Laake, J.-P. S. et al. The association between depressive symptoms and systemic inflammation in people with type 2 diabetes: findings from the South London Diabetes Study. Diabetes Care 37 , 2186–2192 (2014).

Hayashino, Y., Mashitani, T., Tsujii, S. & Ishii, H. Elevated levels of hs-CRP are associated with high prevalence of depression in Japanese patients with type 2 diabetes: the Diabetes Distress and Care Registry at Tenri (DDCRT 6). Diabetes Care 37 , 2459–2465 (2014).

Moulton, C. D., Pickup, J. C. & Ismail, K. The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol. 3 , 461–471 (2015).

Carson, A. J. et al. Depression after stroke and lesion location: a systematic review. Lancet 356 , 122–126 (2000).

Wei, N. et al. Post-stroke depression and lesion location: a systematic review. J. Neurol. 262 , 81–90 (2014).

Padmanabhan, J. L. et al. A human depression circuit derived from focal brain lesions. Biol. Psychiatry 86 , 749–758 (2019).

Allida, S. et al. Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression after stroke. Cochrane Database Syst. Rev. 1 , CD0033437 (2020).

Gold, S. M. et al. Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. Hum. Brain Mapp. 35 , 30–37 (2012).

Rossi, S. et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. Neurology 89 , 1338–1347 (2017).

Corallo, F. et al. A complex relation between depression and multiple sclerosis: a descriptive review. Neurol. Sci. 40 , 1551–1558 (2019).

Qato, D. M., Ozenberger, K. & Olfson, M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 319 , 2289–2298 (2018).

Verbeek, D. E. P., van Riezen, J., de Boer, R. A., van Melle, J. P. & de Jonge, P. A review on the putative association between beta-blockers and depression. Heart Fail. Clin. 7 , 89–99 (2011).

Salagre, E., Fernandes, B. S., Dodd, S., Brownstein, D. J. & Berk, M. Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials. J. Affect. Disord. 200 , 235–242 (2016).

Kovacs, D., Kovacs, P., Eszlari, N., Gonda, X. & Juhasz, G. Psychological side effects of immune therapies: symptoms and pathomechanism. Curr. Opin. Pharmacol. 29 , 97–103 (2016).

Udina, M. et al. Interferon-induced depression in chronic hepatitis C. J. Clin. Psychiatry 73 , 1128–1138 (2012).

Schaefer, M. et al. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann. Intern. Med. 157 , 94–103 (2012).

Mann, T. K., Dail, R. B. & Bailey, D. E. Cognitive and affective symptoms experienced by cancer patients receiving high-dose intravenous interleukin 2 therapy: an integrative literature review. Cancer Nurs. 39 , 349–357 (2016).

DellaGioia, N. & Hannestad, J. A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci. Biobehav. Rev. 34 , 130–143 (2010).

Weinberger, A. H. et al. Depression and cigarette smoking behavior: a critical review of population-based studies. Am. J. Drug. Alcohol. Abuse 43 , 416–431 (2016).

Forouzanfar, M. H. et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 , 1659–1724 (2016).

Chauhan, G. et al. Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting. Neurology 92 , e486–e503 (2019).

PubMed Central Google Scholar

Belbasis, L., Bellou, V., Evangelou, E., Ioannidis, J. P. A. & Tzoulaki, I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 14 , 263–273 (2015).

Chaiton, M. O., Cohen, J. E., OtextquotesingleLoughlin, J. & Rehm, J. A systematic review of longitudinal studies on the association between depression and smoking in adolescents. BMC Public. Health 9 , 356 (2009).

Ho, S. Y., Alnashri, N., Rohde, D., Murphy, P. & Doyle, F. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with chronic respiratory conditions. Gen. Hosp. Psychiatry 37 , 399–407 (2015).

Patten, S. B., Williams, J. V. & Bulloch, A. G. Major depressive episodes and mortality in the Canadian household population. J. Affect. Disord. 242 , 165–171 (2019).

Choi, K. W. et al. Assessment of bidirectional relationships between physical activity and depression among adults. JAMA Psychiatry 76 , 399–408 (2019).

Whooley, M. A. et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 300 , 2379–2388 (2008). This study demonstrates that the association between depressive symptoms and adverse cardiovascular events in patients with coronary heart disease is largely explained by behavioural factors, particularly physical inactivity .

Boden, J. M. & Fergusson, D. M. Alcohol and depression. Addiction 106 , 906–914 (2011).

Lassale, C. et al. Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. Mol. Psychiatry 24 , 965–986 (2018).

Molendijk, M., Molero, P., Ortuño Sánchez-Pedreño, F., Van der Does, W. & Angel Martínez-González, M. Diet quality and depression risk: a systematic review and dose-response meta-analysis of prospective studies. J. Affect. Disord. 226 , 346–354 (2018).

Martínez-González, M. A., Gea, A. & Ruiz-Canela, M. The Mediterranean diet and cardiovascular health. Circulation Res. 124 , 779–798 (2019).

Bot, M. et al. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms. JAMA 321 , 858–868 (2019).

Mausbach, B. T., Schwab, R. B. & Irwin, S. A. Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res. Treat. 152 , 239–246 (2015).

Kessing, D., Denollet, J., Widdershoven, J. & Kupper, N. Psychological determinants of heart failure self-care. Psychosom. Med. 78 , 412–431 (2016).

Brown, S. A. et al. Biobehavioral determinants of glycemic control in type 2 diabetes: a systematic review and meta-analysis. Patient Educ. Couns. 99 , 1558–1567 (2016).

Rieckmann, N. et al. Course of depressive symptoms and medication adherence after acute coronary syndromes. J. Am. Coll. Cardiol. 48 , 2218–2222 (2006).

Folkman, S. in Encyclopedia of Behavioral Medicine (eds Gellman, M. D. & Turner, J. R.) 1913–1915 (Springer, 2013).

Heijmans, M. et al. The stress of being chronically ill: from disease-specific to task-specific aspects. J. Behav. Med. 27 , 255–271 (2004).

Moss-Morris, R. Adjusting to chronic illness: time for a unified theory. Br. J. Health Psychol. 18 , 681–686 (2013).

Clarke, D. M. & Currie, K. C. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med. J. Aust. 190 , S54–S60 (2009).

Detweiler-Bedell, J. B., Friedman, M. A., Leventhal, H., Miller, I. W. & Leventhal, E. A. Integrating co-morbid depression and chronic physical disease management: identifying and resolving failures in self-regulation. Clin. Psychol. Rev. 28 , 1426–1446 (2008).

Sirois, F. M., Kitner, R. & Hirsch, J. K. Self-compassion, affect, and health-promoting behaviors. Health Psychol. 34 , 661–669 (2015).

Schiavon, C. C., Marchetti, E., Gurgel, L. G., Busnello, F. M. & Reppold, C. T. Optimism and hope in chronic disease: a systematic review. Front. Psychol. 7 , 2022 (2016).

Leventhal, H., Diefenbach, M. & Leventhal, E. A. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cognit. Ther. Res. 16 , 143–163 (1992).

Trudel-Fitzgerald, C. et al. The relationship of perfectionism with psychological symptoms in cancer patients and the contributing role of hyperarousability and coping. Psychol. Health 32 , 381–401 (2017).

Leventhal, H., Brissette, I. & Leventhal, E. A. in The Self-regulation of Health and Illness Behaviour (eds Cameron, L. D. & Leventhal, H.) 42–65 (Psychology Press, 2003).

Hagger, M. S., Koch, S., Chatzisarantis, N. L. D. & Orbell, S. The common sense model of self-regulation: meta-analysis and test of a process model. Psychol. Bull. 143 , 1117–1154 (2017).

Uhlenbusch, N. et al. Depression and anxiety in patients with different rare chronic diseases: a cross-sectional study. PLoS ONE 14 , e0211343 (2019).

Edwards, R. R., Cahalan, C., Mensing, G., Smith, M. & Haythornthwaite, J. A. Pain, catastrophizing, and depression in the rheumatic diseases. Nat. Rev. Rheumatol. 7 , 216–224 (2011).

Edwards, R. R., Bingham, C. O., Bathon, J. & Haythornthwaite, J. A. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Rheum. 55 , 325–332 (2006).

Hudson, J. L. & Moss-Morris, R. Treating illness distress in chronic illness. Eur. Psychol. 24 , 26–37 (2019).

Neff, K. Self-compassion: an alternative conceptualization of a healthy attitude toward oneself. Self Identity 2 , 85–101 (2003).

Pinto-Gouveia, J., Duarte, C., Matos, M. & Fráguas, S. The protective role of self-compassion in relation to psychopathology symptoms and quality of life in chronic and in cancer patients. Clin. Psychol. Psychother. 21 , 311–323 (2013).

Przezdziecki, A. et al. My changed body: breast cancer, body image, distress and self-compassion. Psychooncology 22 , 1872–1879 (2012).

Sirois, F. M. & Rowse, G. The role of self-compassion in chronic illness care. J. Clin. Outcome Manag. 23 , 521–527 (2016).

Stange, J. P., Alloy, L. B. & Fresco, D. M. Inflexibility as a vulnerability to depression: a systematic qualitative review. Clin. Psychol. Sci. Pract. 24 , 245–276 (2017).

Gentili, C. et al. Psychological flexibility as a resilience factor in individuals with chronic pain. Front. Psychol. 10 , 2016 (2019).

Dimidjian, S., Barrera, M., Martell, C., Muñoz, R. F. & Lewinsohn, P. M. The origins and current status of behavioral activation treatments for depression. Annu. Rev. Clin. Psychol. 7 , 1–38 (2011).

Shear, M. K. et al. Optimizing treatment of complicated grief: a randomized clinical trial. JAMA Psychiatry 73 , 685–694 (2016).

Whooley, M. A., Avins, A. L., Miranda, J. & Browner, W. S. Case-finding instruments for depression. J. Gen. Intern. Med. 12 , 439–445 (1997).

Bosanquet, K. et al. Diagnostic accuracy of the Whooley questions for the identification of depression: a diagnostic meta-analysis. BMJ Open 5 , e008913 (2015). This paper provides a quantitative overview of the diagnostic accuracy of screening for depression .

Colquhoun, D. M. et al. Screening, referral and treatment for depression in patients with coronary heart disease. Med. J. Aust. 198 , 483–484 (2013).

World Health Organization. mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings – version 2 (WHO, 2016).

Shepard, N. & Parker, C. Depression in adults: recognition and management. Clin. Pharm. https://doi.org/10.1211/cp.2017.20202439 (2017).

Article Google Scholar

Kroenke, K., Spitzer, R. L. & Williams, J. B. W. The patient health questionnaire-2. Med. Care 41 , 1284–1292 (2003).

Manea, L. et al. Identifying depression with the PHQ-2: a diagnostic meta-analysis. J. Affect. Disord. 203 , 382–395 (2016).

Whooley, M. A. Screening for depression — a tale of two questions. JAMA Intern. Med. 176 , 436–438 (2016).

Levis, B. et al. Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: systematic review and meta-analysis. JAMA 323 , 2290–2300 (2020).

Kroenke, K., Spitzer, R. L. & Williams, J. B. W. The PHQ-9. J. Gen. Intern. Med. 16 , 606–613 (2001).

Gilbody, S., Richards, D., Brealey, S. & Hewitt, C. Screening for depression in medical settings with the patient health questionnaire (PHQ): a diagnostic meta-analysis. J. Gen. Intern. Med. 22 , 1596–1602 (2007).

Mitchell, A. J., Yadegarfar, M., Gill, J. & Stubbs, B. Case finding and screening clinical utility of the patient health questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies. BJPsych Open 2 , 127–138 (2016).

Archer, J. et al. Collaborative care for depression and anxiety problems. Cochrane Database Syst. Rev. 10 , CD006525 (2012).

Panagioti, M. et al. Association between chronic physical conditions and the effectiveness of collaborative care for depression: an individual participant data meta-analysis. JAMA Psychiatry 73 , 978–989 (2016).

Cipriani, A. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391 , 1357–1366 (2018).

Rayner, L. et al. Antidepressants for depression in physically ill people. Cochrane Database Syst. Rev. 391 , CD007503 (2010). This paper provides a comprehensive, quantitative summary of the efficacy of antidepressants in patients with comorbid medical disorders .

Ostuzzi, G. et al. Efficacy and acceptability of antidepressants in patients with ischemic heart disease. Int. Clin. Psychopharmacol. 34 , 65–75 (2019).

Ostuzzi, G., Benda, L., Costa, E. & Barbui, C. Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: systematic review and meta-analysis. Cancer Treat. Rev. 41 , 714–724 (2015).

Baumeister, H., Hutter, N. & Bengel, J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review. Diabet. Med. 31 , 773–786 (2014).

Price, A. et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J. Neurol. Neurosurg. Psychiatry 82 , 914–923 (2011).

Xu, X. et al. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. Medicine 95 , e5349 (2016).

Bomasang-Layno, E., Fadlon, I., Murray, A. N. & Himelhoch, S. Antidepressive treatments for Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 21 , 833–842 (2015).

Fiest, K. M. et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult. Scler. Relat. Disord. 5 , 12–26 (2016).

Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C. & Hotopf, M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.cd011006.pub3 (2018).

Article PubMed PubMed Central Google Scholar

Fiest, K. M. et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with rheumatoid Arthritis. J. Clin. Rheumatol. 23 , 425–434 (2017).

Fiest, K. M. et al. Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease. BMC Res. Notes 9 , 404 (2016).

Madhusoodanan, S., Velama, U., Parmar, J., Goia, D. & Brenner, R. A current review of cytochrome P450 interactions of psychotropic drugs. Ann. Clin. Psychiatry 26 , 120–138 (2014).

Rosenblat, J. D., Lee, Y. & McIntyre, R. S. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis. J. Affect. Disord. 241 , 484–491 (2018).

Kim, B. Y., Sharafoddini, A., Tran, N., Wen, E. Y. & Lee, J. Consumer mobile apps for potential drug-drug interaction check: systematic review and content analysis using the mobile app rating scale (MARS). JMIR Mhealth Uhealth 6 , e74 (2018).

Apidi, N. A. et al. Mobile medical applications for dosage recommendation, drug adverse reaction, and drug interaction. Ther. Innov. Regul. Sci. 51 , 480–485 (2017).

Eshun-Wilson, I. et al. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.cd008525.pub3 (2018).

Zimmermann-Viehoff, F., Kuehl, L. K., Danker-Hopfe, H., Whooley, M. A. & Otte, C. Antidepressants, autonomic function and mortality in patients with coronary heart disease: data from the heart and soul study. Psychol. Med. 44 , 2975–2984 (2014).

Taylor, D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr. Scand. 118 , 434–442 (2008).

Pizzi, C. et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am. J. Cardiol. 107 , 972–979 (2011).

Beach, S. R. et al. Meta-analysis of selective serotonin reuptake inhibitor–associated QTc prolongation. J. Clin. Psychiatry 75 , e441–e449 (2014).

Assimon, M. M., Brookhart, M. A. & Flythe, J. E. Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. J. Am. Soc. Nephrol. 30 , 611–623 (2019).

Bahar, M. A., Kamp, J., Borgsteede, S. D., Hak, E. & Wilffert, B. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br. J. Clin. Pharmacol. 84 , 2704–2715 (2018).

Köhler-Forsberg, O. et al. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatri. Scand. 139 , 404–419 (2019).

Bu, D., Griffin, G. & Lichtman, A. H. Mechanisms for the anti-inflammatory effects of statins. Curr. Opin. Lipidol. 22 , 165–170 (2011).

Abajo, F. J. de & García-Rodríguez, L. A. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy. Arch. Gen. Psychiatry 65 , 795–803 (2008).

Spina, E., Barbieri, M. A., Cicala, G., Bruno, A. & de Leon, J. Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert. Opin. Drug. Metab. Toxicol. 16 , 31–44 (2020).

Yoon, J. M., Cho, E.-G., Lee, H.-K. & Park, S. M. Antidepressant use and diabetes mellitus risk: a meta-analysis. Korean J. Fam. Med. 34 , 228–240 (2013).

Domecq, J. P. et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 100 , 363–370 (2015).

Roopan, S. & Larsen, E. R. Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. Acta Neuropsychiatr. 29 , 127–139 (2016).

Williams, L. J. et al. Selective serotonin reuptake inhibitors (SSRIs) and markers of bone turnover in men. Calcif. Tissue Int. 103 , 125–130 (2018).

Brännström, J., Lövheim, H., Gustafson, Y. & Nordström, P. Association between antidepressant drug use and hip fracture in older people before and after treatment initiation. JAMA Psychiatry 76 , 172–179 (2019).

Maguire, M. J., Weston, J., Singh, J. & Marson, A. G. Antidepressants for people with epilepsy and depression. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD010682.pub2 (2014).

Monaco, F. & Cicolin, A. Interactions between anticonvulsant and psychoactive drugs. Epilepsia 40 , s71–s76 (1999).

Ogawa, Y. et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst. Rev. 6 , CD001026 (2019).

Gasim, M. et al. Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review. Mult. Scler. Relat. Disord. 26 , 124–156 (2018).

Deutsche Gesellschaft für Neurologie. Idiopathisches Parkinson-Syndrom in Leitlinien für Diagnostik und Therapie in der Neurologie (DGN, 2016).

Lederberg, M. S. & Holland, J. C. in Handbook of Psychotherapy in Cancer Care Ch. 1 (Watson, M. & Kissane, D. W.) 1–14 (John Wiley & Sons, Ltd, 2011).

Faller, H. et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J. Clin. Oncol. 31 , 782–793 (2013).

Okuyama, T., Akechi, T., Mackenzie, L. & Furukawa, T. A. Psychotherapy for depression among advanced, incurable cancer patients: a systematic review and meta-analysis. Cancer Treat. Rev. 56 , 16–27 (2017).

Bortolato, B. et al. Depression in cancer: The many biobehavioral pathways driving tumor progression. Cancer Treat. Rev. 52 , 58–70 (2017).

Lutgendorf, S. K. & Andersen, B. L. Biobehavioral approaches to cancer progression and survival: mechanisms and interventions. Am. Psychologist 70 , 186–197 (2015).

Hartung, T. J. et al. The hospital anxiety and depression scale (HADS) and the 9-item patient health questionnaire (PHQ-9) as screening instruments for depression in patients with cancer: depression screening in oncology. Cancer 123 , 4236–4243 (2017).

Wang, S.-B. et al. Cognitive behavioral therapy for post-stroke depression: a meta-analysis. J. Affect. Disord. 235 , 589–596 (2018).

Hackett, M. L., Anderson, C. S., House, A. & Xia, J. Interventions for treating depression after stroke. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.cd003437.pub3 (2008).

Article PubMed Google Scholar

Ghielen, I. et al. The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson’s disease and Huntington’s disease: two meta-analyses. J. Psychosom. Res. 122 , 43–51 (2019).

Hind, D. et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry 14 , 5 (2014).

Reavell, J., Hopkinson, M., Clarkesmith, D. & Lane, D. A. Effectiveness of cognitive behavioral therapy for depression and anxiety in patients with cardiovascular disease. Psychosom. Med. 80 , 742–753 (2018).

Li, C. et al. A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for patients with diabetes and depression. J. Psychosom. Res. 95 , 44–54 (2017).

Chew, B. H., Vos, R. C., Metzendorf, M.-I., Scholten, R. J. & Rutten, G. E. Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. Cochrane Database Syst. Rev. 9 , CD011469 (2017).

Graham, C. D., Gouick, J., Krahé, C. & Gillanders, D. A systematic review of the use of acceptance and commitment therapy (ACT) in chronic disease and long-term conditions. Clin. Psychol. Rev. 46 , 46–58 (2016).

Gold, S. M. et al. Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework. Lancet Psychiatry 4 , 725–732 (2017).

UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361 , 799–808 (2003).

Meyer, J. P., Swetter, S. K. & Kellner, C. H. Electroconvulsive therapy in geriatric psychiatry: a selective review. Psychiatr. Clin. North. Am. 41 , 79–93 (2018).

van Diermen, L. et al. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br. J. Psychiatry 212 , 71–80 (2018).

Semkovska, M. & McLoughlin, D. M. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol. Psychiatry 68 , 568–577 (2010).

Mutz, J. et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ 364 , l1079 (2019).

Academy of Medical Sciences. Multimorbidity: a priority for global health research (Academy of Medical Sciences, 2018).

Beran, D., Perel, P. & Miranda, J. J. Forty years since Alma-Ata: do we need a new model for noncommunicable diseases? J. Glob. Health 9 , 010316 (2019).

Brandt, L. R. et al. Addressing depression comorbid with diabetes or hypertension in resource-poor settings: a qualitative study about user perception of a nurse-supported smartphone app in Peru. JMIR Ment. Health 6 , e11701 (2019).

Menezes, P. et al. Use of a mobile phone app to treat depression comorbid with hypertension or diabetes: a pilot study in Brazil and Peru. JMIR Ment. Health 6 , e11698 (2019).

Gellis, Z. D., Kenaley, B. L. & Have, T. T. Integrated telehealth care for chronic illness and depression in geriatric home care patients: the Integrated Telehealth Education and Activation of Mood (I-TEAM) study. J. Am. Geriatr. Soc. 62 , 889–895 (2014).

Butow, P. et al. Comparison of implementation strategies to influence adherence to the clinical pathway for screening, assessment and management of anxiety and depression in adult cancer patients (ADAPT CP): study protocol of a cluster randomised controlled trial. BMC Cancer 18 , 1077 (2018).

Woltmann, E. et al. Comparative effectiveness of collaborative chronic care models for mental health conditions across primary, specialty, and behavioral health care settings: systematic review and meta-analysis. Am. J. Psychiatry 169 , 790–804 (2012).

Stein, D. J. et al. Integrating mental health with other non-communicable diseases. BMJ 364 , l295 (2019).

Firth, J. et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 6 , 675–712 (2019).

Labrique, A., Vasudevan, L., Mehl, G., Rosskam, E. & Hyder, A. A. Digital health and health systems of the future. Glob. Health Sci. Pract. 6 , S1–S4 (2018).

Peiris, D., Miranda, J. J. & Mohr, D. C. Going beyond killer apps: building a better mHealth evidence base. BMJ Glob. Health 3 , e000676 (2018).

Chandrashekar, P. Do mental health mobile apps work: evidence and recommendations for designing high-efficacy mental health mobile apps. mHealth 4 , 6 (2018).

Hoermann, S., McCabe, K. L., Milne, D. N. & Calvo, R. A. Application of synchronous text-based dialogue systems in mental health interventions: systematic review. J. Med. Internet Res. 19 , e267 (2017).

Kroenke, K. et al. Effect of telecare management on pain and depression in patients with cancer. JAMA 304 , 163–171 (2010).

Diez-Canseco, F. et al. Integration of a technology-based mental health screening program into routine practices of primary health care services in Peru (the Allillanchu Project): development and implementation. J. Med. Internet Res. 20 , e100 (2018).

Cavero, V. et al. Provision of mental health care within primary care in Peru: a qualitative study exploring the perspectives of psychologists, primary health care providers, and patients. Wellcome Open. Res. 3 , 9 (2018).

Nobis, S. et al. Efficacy of a web-based intervention with mobile phone support in treating depressive symptoms in adults with type 1 and type 2 diabetes: a randomized controlled trial. Diabetes Care 38 , 776–783 (2015).

Nobis, S. et al. Web-based intervention for depressive symptoms in adults with types 1 and 2 diabetes mellitus: a health economic evaluation. Br. J. Psychiatry 212 , 199–206 (2018).

Yoo, S. J. C., Nyman, J. A., Cheville, A. L. & Kroenke, K. Cost effectiveness of telecare management for pain and depression in patients with cancer: results from a randomized trial. Gen. Hosp. Psychiatry 36 , 599–606 (2014).

Chibanda, D. et al. Effect of a primary care-based psychological intervention on symptoms of common mental disorders in Zimbabwe. JAMA 316 , 2618–2626 (2016). This study demonstrates the feasibility and effectiveness of task-shifting treatment strategies to non-health professionals, augmenting possibilities for reach and adoption of treatment efforts in low-resource settings .

Mehta, S., Peynenburg, V. A. & Hadjistavropoulos, H. D. Internet-delivered cognitive behaviour therapy for chronic health conditions: a systematic review and meta-analysis. J. Behav. Med. 42 , 169–187 (2018).

Fischer, A. et al. An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. Lancet Psychiatry 2 , 217–223 (2015).

Schröder, J. et al. Efficacy of a psychological online intervention for depression in people with epilepsy: a randomized controlled trial. Epilepsia 55 , 2069–2076 (2014).

Herring, M. P., Puetz, T. W., O’Connor, P. J. & Dishman, R. K. Effect of exercise training on depressive symptoms among patients with a chronic illness. Arch. Intern. Med. 172 , 101–111 (2012).

Blumenthal, J. A. et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease. J. Am. Coll. Cardiol. 60 , 1053–1063 (2012).

Blumenthal, J. A. et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure. JAMA 308 , 465–474 (2012).

Dalgas, U., Stenager, E., Sloth, M. & Stenager, E. The effect of exercise on depressive symptoms in multiple sclerosis based on a meta-analysis and critical review of the literature. Eur. J. Neurol. 22 , e34 (2015).

Kelley, G. A., Kelley, K. S. & Hootman, J. M. Effects of exercise on depression in adults with arthritis: a systematic review with meta-analysis of randomized controlled trials. Arthritis Res. Ther. 17 , 21 (2015).

Fang, F. et al. Suicide and cardiovascular death after a cancer diagnosis. N. Engl. J. Med. 366 , 1310–1318 (2012).

Zaorsky, N. G. et al. Suicide among cancer patients. Nat. Commun. 10 , 207 (2019).

Bolton, J. M., Walld, R., Chateau, D., Finlayson, G. & Sareen, J. Risk of suicide and suicide attempts associated with physical disorders: a population-based, balancing score-matched analysis. Psychol. Med. 45 , 495–504 (2014).

Wang, B., An, X., Shi, X. & Zhang, J.-A. Management of endocrine disease: suicide risk in patients with diabetes: a systematic review and meta-analysis. Eur. J. Endocrinol. 177 , R169–R181 (2017).

Pompili, M. et al. Suicide risk in type 1 diabetes mellitus: a systematic review. J. Psychosom. Res. 76 , 352–360 (2014).

Erlangsen, A. et al. Association between neurological disorders and death by suicide in Denmark. JAMA 323 , 444–454 (2020).

Ahmedani, B. K. et al. Health care contacts in the year before suicide death. J. Gen. Intern. Med. 29 , 870–877 (2014).

Katon, W. J. et al. Collaborative care for patients with depression and chronic illnesses. N. Engl. J. Med. 363 , 2611–2620 (2010).

Li, M. et al. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology 26 , 573–587 (2016).

Atlantis, E., Fahey, P. & Foster, J. Collaborative care for comorbid depression and diabetes: a systematic review and meta-analysis. BMJ Open 4 , e004706 (2014).

Tully, P. J. & Baumeister, H. Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 5 , e009128 (2015).

Bullinger, M. & Quitmann, J. Quality of life as patient-reported outcomes: principles of assessment. Dialogues Clin. Neurosci. 16 , 137–145 (2014).

Bullinger, M. in Advances in Experimental Medicine and Biology 113–122 (Kluwer Academic Publishers, 2003).

John, E. Ware, Jr. & Gandek, B. The SF-36 health survey: development and use in mental health research and the IQOLA project. Int. J. Ment. Health 23 , 49–73 (1994).

Skevington, S. M., Lotfy, M. & O’Connell, K. A. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual. Life Res. 13 , 299–310 (2004).

Devlin, N. J. & Brooks, R. EQ-5D and the EuroQol group: past, present and future. Appl. Health Econ. Health Policy 15 , 127–137 (2017).

Cocks, K., King, M. T., Velikova, G., Fayers, P. M. & Brown, J. M. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur. J. Cancer 44 , 1793–1798 (2008).

Liao, S.-C., Ma, H.-M., Lin, Y.-L. & Huang, W.-L. Functioning and quality of life in patients with somatic symptom disorder: the association with comorbid depression. Compr. Psychiatry 90 , 88–94 (2019).

Gao, K., Su, M., Sweet, J. & Calabrese, J. R. Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. J. Affect. Disord. 244 , 9–15 (2019).

DeJean, D., Giacomini, M., Vanstone, M. & Brundisini, F. Patient experiences of depression and anxiety with chronic disease: a systematic review and qualitative meta-synthesis. Ont. Health Technol. Assess. Ser. 13 , 1–33 (2013).

Sluijs, J. F. et al. Illness burden and physical outcomes associated with collaborative care in patients with comorbid depressive disorder in chronic medical conditions: a systematic review and meta-analysis. Gen. Hosp. Psychiatry 50 , 1–14 (2018).

Schwartz, C. E. et al. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual. Life Res. 15 , 1533–1550 (2006).

Kristofferzon, M.-L., Engström, M. & Nilsson, A. Coping mediates the relationship between sense of coherence and mental quality of life in patients with chronic illness: a cross-sectional study. Qual. Life Res. 27 , 1855–1863 (2018).

Park, S. J., Rim, S. J., Kim, C. E. & Park, S. Effect of comorbid depression on health-related quality of life of patients with chronic diseases: a South Korean nationwide study (2007–2015). J. Psychosom. Res. 116 , 17–21 (2019).

Kang, H.-J. et al. Comorbidity of depression with physical disorders: research and clinical implications. Chonnam Med. J. 51 , 8–18 (2015).

Egede, L. E. & Hernández-Tejada, M. A. Effect of comorbid depression on quality of life in adults with type 2 diabetes. Expert. Rev. Pharmacoeconomics Outcomes Res. 13 , 83–91 (2013).

Amoozegar, F. Depression comorbidity in migraine. Int. Rev. Psychiatry 29 , 504–515 (2017).

Shin, D. W. et al. Health-related quality of life, perceived social support, and depression in disease-free survivors who underwent curative surgery only for prostate, kidney and bladder cancer: comparison among survivors and with the general population. Cancer Res. Treat. 51 , 289–299 (2019).

Rodrigues, K. C. et al. Assessment of depression, anxiety, quality of life, and coping in long-standing multiple endocrine neoplasia type 2 patients. Thyroid 27 , 693–706 (2017).

Lemmens, L. C., Molema, C. C. M., Versnel, N., Baan, C. A. & de Bruin, S. R. Integrated care programs for patients with psychological comorbidity: a systematic review and meta-analysis. J. Psychosom. Res. 79 , 580–594 (2015).

Vyas, A., Babcock, Z. & Kogut, S. Impact of depression treatment on health-related quality of life among adults with cancer and depression: a population-level analysis. J. Cancer Surviv. 11 , 624–633 (2017).

Alenzi, E. O. & Sambamoorthi, U. Depression treatment and health-related quality of life among adults with diabetes and depression. Qual. Life Res. 25 , 1517–1525 (2015).

Shah, D., Rai, P., Dwibedi, N. & Sambamoorthi, U. Treatment for depression and health-related quality of life among adults with arthritis. Psychiatr. Q. 89 , 129–140 (2017).

Baumeister, H., Hutter, N. & Bengel, J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst. Rev. 9 , CD008012 (2011).

Kearns, B. et al. The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation. BMC Health Serv. Res. 17 , 78 (2017).

Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. EMA https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf (2005).

FDA. Patient-reported outcome measures: use in medical product development to support labeling claims. FDA https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims (2009).

Minden, S. L. et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82 , 174–181 (2013).

Siu, A. L. et al. Screening for depression in adults: US preventive services task force recommendation statement. JAMA 315 , 380–387 (2016).

Canadian Task Force on Preventive Health Care. et al. Recommendations on screening for depression in adults. Can. Med. Assoc. J. 185 , 775–782 (2013).

Thombs, B. D. & Ziegelstein, R. C. Does depression screening improve depression outcomes in primary care? BMJ 348 , g1253–g1253 (2014).

Ferrari, F. & Villa, R. F. The neurobiology of depression: an integrated overview from biological theories to clinical evidence. Mol. Neurobiol. 54 , 4847–4865 (2016).

Pilevarzadeh, M. et al. Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res. Treat. 176 , 519–533 (2019).

Walker, J. et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry 1 , 343–350 (2014).

Li, Z., Li, Y., Chen, L., Chen, P. & Hu, Y. Prevalence of depression in patients with hypertension: a systematic review and meta-analysis. Medicine 94 , e1317 (2015).

Ormel, J., Oldehinkel, A. J., Nolen, W. A. & Vollebergh, W. Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects. Arch. Gen. Psychiatry 61 , 387–392 (2004).

Marmot, M. et al. WHO European review of social determinants of health and the health divide. Lancet 380 , 1011–1029 (2012).

Hughes, K. et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. Lancet Public Health 2 , e356–e366 (2017).

Cuijpers, P., Stringaris, A. & Wolpert, M. Treatment outcomes for depression: challenges and opportunities. Lancet Psychiatry 17 , 30036–30045 (2020).

Suglia, S. F. et al. Childhood and adolescent adversity and cardiometabolic outcomes: a scientific statement from the American Heart Association. Circulation 137 , e15–e28 (2018).

Heim, C. M., Entringer, S. & Buss, C. Translating basic research knowledge on the biological embedding of early-life stress into novel approaches for the developmental programming of lifelong health. Psychoneuroendocrinology 105 , 123–137 (2019).

Stringhini, S. et al. Socioeconomic status and the 25×25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women. Lancet 389 , 1229–1237 (2017).

Lorant, V. et al. Socioeconomic inequalities in depression: a meta-analysis. Am. J. Epidemiol. 157 , 98–112 (2003).

Saraceno, B., Levav, I. & Kohn, R. The public mental health significance of research on socio-economic factors in schizophrenia and major depression. World Psychiatry 4 , 181–185 (2005).

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn (American Psychiatric Association, 2013).

Scottish Government Polypharmacy Model of Care Group. Polypharmacy Guidance, Realistic Prescribing 3rd edn (Scottish Government, 2018).

van den Beuken-van Everdingen, M. H. J., Hochstenbach, L. M. J., Joosten, E. A. J., Tjan-Heijnen, V. C. G. & Janssen, D. J. A. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J. Pain. Symptom Manage 51 , 1070–1090.e9 (2016).

Drewes, A. M. et al. Gastrointestinal pain. Nat. Rev. Dis. Prim. 6 , 1 (2020).

Bair, M. J. et al. Prevalence of pain and association with quality of life, depression and glycaemic control in patients with diabetes. Diabet. Med. 27 , 578–584 (2010).

Antonini, A. et al. Pain in Parkinson’s disease: facts and uncertainties. Eur. J. Neurol. 25 , 917-e69 (2018).

Means-Christensen, A. J., Roy-Byrne, P. P., Sherbourne, C. D., Craske, M. G. & Stein, M. B. Relationships among pain, anxiety, and depression in primary care. Depress. Anxiety 25 , 593–600 (2008).

Gerrits, M. M. J. G., van Oppen, P., van Marwijk, H. W. J., Penninx, B. W. J. H. & van der Horst, H. E. Pain and the onset of depressive and anxiety disorders. Pain 155 , 53–59 (2014).

Stubbs, B. et al. Depression and pain: primary data and meta-analysis among 237 952 people across 47 low- and middle-income countries. Psychol. Med. 47 , 2906–2917 (2017).

DeVeaugh-Geiss, A. M. et al. The adverse effects of comorbid pain on depression outcomes in primary care patients: results from the ARTIST trial. Pain Med. 11 , 732–741 (2010).

Gerrits, M. M. J. G. et al. Pain, not chronic disease, is associated with the recurrence of depressive and anxiety disorders. BMC Psychiatry 14 , 187 (2014).

World Health Organization. Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents (WHO, 2018).

Chou, R. et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians Clinical Practice Guideline. Ann. Intern. Med. 166 , 480–492 (2017).

Download references

Acknowledgements

S.M.G. receives funding from the Deutsche Forschungsgemeinschaft (GO1357/5-2; 8-2), the European Commission (IMI2 859366), the German Federal Ministry of Health (BMG-BVA 2520FSB431) and the National MS Society (MB-1707-28359; RG-1507-05418). J.J.M. has received support from the Alliance for Health Policy and Systems Research (HQHSR1206660), the Bernard Lown Scholars in Cardiovascular Health Program at Harvard T.H. Chan School of Public Health (BLSCHP-1902), Bloomberg Philanthropies, FONDECYT via CIENCIACTIVA/CONCYTEC, British Council, British Embassy and the Newton-Paulet Fund (223-2018, 224-2018), DFID/MRC/Wellcome Global Health Trials (MR/M007405/1), Fogarty International Center (R21TW009982, D71TW010877), Grand Challenges Canada (0335-04), Inter-American Institute for Global Change Research (IAI CRN3036), International Development Research Center Canada (IDRC 106887, 108167), Medical Research Council (MR/P008984/1, MR/P024408/1, MR/P02386X/1), National Cancer Institute (1P20CA217231), National Heart, Lung and Blood Institute (HHSN268200900033C, 5U01HL114180, 1UM1HL134590), National Institute of Mental Health (1U19MH098780), Swiss National Science Foundation (40P740-160366), Wellcome Trust (074833/Z/04/Z, 093541/Z/10/Z, 103994/Z/14/Z, 107435/Z/15/Z, 205177/Z/16/Z, 214185/Z/18/Z, 218743/Z/19/Z) and the World Diabetes Foundation (WDF15-1224). C.O. has received funding from the Deutsche Forschungsgemeinschaft (OT 209/7-3; 14-1), the European Commission (IMI2 859366) and the German Federal Ministry of Education and Research (KS2017-067). The authors thank V. Stiglbauer (Charité – Universitätsmedizin Berlin) for help with formatting of the manuscript draft.

Author information

Authors and affiliations.

Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health (BIH), Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin, Berlin, Germany

Stefan M. Gold & Christian Otte

Charité – Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin Institute of Health (BIH), Medizinische Klinik m.S. Psychosomatik, Campus Benjamin Franklin, Berlin, Germany

Stefan M. Gold

Institut für Neuroimmunologie und Multiple Sklerose (INIMS), Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Department for Affective Disorders, Aarhus University Hospital - Psychiatry, Aarhus, Denmark

Ole Köhler-Forsberg

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

Psychosis Research Unit, Aarhus University Hospital - Psychiatry, Aarhus, Denmark

Psychology Department, Institute of Psychology, Psychiatry and Neuroscience, King’s College London (KCL), Guy’s Hospital Campus, London Bridge, London, UK

Rona Moss-Morris

Abteilung für Medizinische Psychologie und Medizinische Soziologie, Universitätsklinikum Leipzig, Leipzig, Germany

Anja Mehnert

CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru

J. Jaime Miranda

Institut und Poliklinik für Medizinische Psychologie, Unversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Monika Bullinger

Department of Behavioural Science and Health, University College London, London, UK

Andrew Steptoe

University of California, San Francisco (UCSF), San Francisco VA Health Care System, San Francisco, CA, USA

Mary A. Whooley

You can also search for this author in PubMed Google Scholar

Contributions

Introduction (S.M.G. and C.O.); Epidemiology (O.K.-F. and M.A.W.); Mechanisms/pathophysiology (S.M.G., O.K.-F., R.M.-M. and A.S.); Diagnosis, screening and prevention (M.A.W. and C.O.); Management (S.M.G., O.K.-F., A.M., J.J.M. and C.O.); Quality of life (M.B.); Outlook (S.M.G.); Overview of Primer (S.M.G. and C.O.).

Corresponding author

Correspondence to Stefan M. Gold .

Ethics declarations

Competing interests.

S.M.G. reports personal fees from Almirall SA, Celgene, Forum für Medizinische Fortbildung (FomF) and Mylan GmbH, and in-kind research contributions from GAIA Group. R.M.-M. reports personal fees from Mahana Therapeutics and is a beneficiary of a license agreement between Mahana Therapeutics and King’s College London. C.O. reports personal fees from Allergan, Ferring, Fortbildungskolleg, Limes Kliniken, Medical Tribune, MedOnline, Neuraxpharm, Sage Therapeutics and Stillachhaus. All other authors declare no competing interests.

Additional information

Peer review information.

Nature Reviews Disease Primers thanks C. Caltagirone, C. Pae, S. Patten, P. De Jonge, Y. Uchitomi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Gold, S.M., Köhler-Forsberg, O., Moss-Morris, R. et al. Comorbid depression in medical diseases. Nat Rev Dis Primers 6 , 69 (2020). https://doi.org/10.1038/s41572-020-0200-2

Download citation

Accepted : 03 July 2020

Published : 20 August 2020

DOI : https://doi.org/10.1038/s41572-020-0200-2

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

The effect of outdoor activities on the medical expenditure of older people: multiple chain mediating effects of health benefits.

BMC Public Health (2024)

Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection

Christina N. Sun
Lucas A. Berenbrok
James M. Stevenson

Neuropsychopharmacology (2024)

Das Deutsche Zentrum für Psychische Gesundheit

Melissa G. Halil
Irina Baskow
Andreas Heinz

Der Nervenarzt (2024)

Prospective trajectories of depression predict mortality in cancer patients

Drishti Enna Sanghvi
Mark Shuquan Chen
George A. Bonanno

Journal of Behavioral Medicine (2024)

Unraveling the Role of the Blood-Brain Barrier in the Pathophysiology of Depression: Recent Advances and Future Perspectives

Shamili Mariya Varghese
Shashikant Patel
Sumana Chakravarty

Molecular Neurobiology (2024)

Quick links

Explore articles by subject
Guide to authors
Editorial policies

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

COMMENTS

Adapting the Incredible Years child dinosaur social ...
Young children who are referred to mental health agencies because of oppositional defiant disorder (ODD) and conduct problems (CP) frequently have comorbid diagnoses or symptoms such as attention deficit disorder (ADD) with or without hyperactivity (ADHD), language/learning and developmental, or autism spectrum disorders.
(PDF) Adapting the Incredible Years child dinosaur social ...
Young children who are referred to mental health agencies because of oppositional defiant disorder (ODD) and conduct problems (CP) frequently have comorbid diagnoses or symptoms such as...
Adapting the Incredible Years child dinosaur social ...
programme offered to children with comorbid issues is successful at reducing behaviour problems and increasing social and emotional competence. This article examines ways in which this small group therapy programme is tailored to address the individual goals of each child so that the intervention is developmentally and therapeutically appropriate.
Adapting the Incredible Years Child Dinosaur Social ...
Research has shown that the Incredible Years Child Dinosaur programme offered to children with comorbid issues is successful at reducing behaviour problems and increasing social and emotional competence.
Review: Comprehensive treatments for youth comorbidity ...
Most EBTs were developed to treat one diagnosis or problem (or a small homogenous cluster), but most clinically referred youths present with multiple disorders and problems. Three emerging approaches may help address the comorbidity that is so common in treated youths.
Care Management of Comorbid Medical and Psychiatric Illness ...
The authors supplemented their findings by describing three key pillars of effective care management, as well as specific interventions to offer patients based on their psychiatric diagnoses and illness severity.
Clinical decision support for patients with comorbidities
Foreword. The purpose of clinical decision support is “to translate knowledge into evidence-based practice in clinical settings.”1 Clinical decision support. can improve healthcare in a range of ways. It can reduce medical errors; it can ensure that healthcare professionals follow guidelines; and it can also save costs.2.
Assessment of Intellectual Disabilities (ID) and Comorbid ...
Current diagnostic practice guidelines emphasize the importance of assessing intellectual ability and adaptive functioning to make a differential diagnosis, but practitioners should also take into consideration an investigation of etiology and comorbid mental, emotional, and behavioral disorders.
Content and objectives of Dina dinosaur social skills and ...
Adapting the Incredible Years child dinosaur social, emotional, and problem-solving intervention to address comorbid diagnoses. Article. Full-text available. May 2008. Carolyn...
Comorbid depression in medical diseases | Nature Reviews ...
This Primer discusses the epidemiology, mechanisms, diagnosis and treatment of comorbid depression in patients with medical diseases.

To read this content please select one of the options below:

Corrigendum:

Related articles

Report an issue or find answers to frequently asked questions

Incredible Years Blog

Adapting the Incredible Years Child Dinosaur Social, Emotional, and Problem-Solving Intervention to Address Co-Morbid Diagnoses

Recent Post

5 Social Emotional Learning (SEL) Classroom Management Techniques

Healthy Parent-Teacher Relationships: Key Tips for Success

How IY Autism Parenting Programs Can Support Families

New Zealand is Truly Incredible

Group-Based Parenting Programs: Strengthening Parental Engagement

Posts by Tag

Care Management of Comorbid Medical and Psychiatric Illness: A Conceptual Framework for Improving Equity of Care

Philip Wang

Matthew Ruble

Evidence-Based Models

General Considerations

Specific Interventions

Universal interventions

Interventions for mild anxiety and depression

Interventions for moderate anxiety and depression

Interventions for mild SUDs

Interventions for moderate SUDs

Interventions for severe psychiatric conditions

Measuring Impact

Moving Forward

Acknowledgments

Author Disclosure Statement

Funding Information

Assessment of Intellectual Disabilities (ID) and Comorbid Disorders in Children

Cite this chapter

Access this chapter

Similar content being viewed by others

Assessment of Intellectual Disabilities: Considerations for Dual Diagnosis

Psychiatric Disorders in Children and Adolescents with Intellectual Disability

Intellectual Disabilities

Author information

Corresponding author

Editor information

Rights and permissions

Copyright information

About this chapter

Download citation

Share this chapter

Comorbid depression in medical diseases

Access options

Similar content being viewed by others

Association of pre-existing depression with all-cause, cancer-related, and noncancer-related mortality among 5-year cancer survivors: a population-based cohort study

Major depressive disorder

Acknowledgements

Author information

Contributions

Corresponding author

Ethics declarations

Additional information

Publisher’s note

Related links

Rights and permissions

About this article

Share this article

This article is cited by

Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection

Das Deutsche Zentrum für Psychische Gesundheit

Prospective trajectories of depression predict mortality in cancer patients

Unraveling the Role of the Blood-Brain Barrier in the Pathophysiology of Depression: Recent Advances and Future Perspectives

Quick links

COMMENTS